CA3193856A1 - Cannabis plant derived extracellular vesicles and therapeutic methods using the same - Google Patents
Cannabis plant derived extracellular vesicles and therapeutic methods using the sameInfo
- Publication number
- CA3193856A1 CA3193856A1 CA3193856A CA3193856A CA3193856A1 CA 3193856 A1 CA3193856 A1 CA 3193856A1 CA 3193856 A CA3193856 A CA 3193856A CA 3193856 A CA3193856 A CA 3193856A CA 3193856 A1 CA3193856 A1 CA 3193856A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- composition
- cpevs
- evs
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218236 Cannabis Species 0.000 title claims 2
- 238000002560 therapeutic procedure Methods 0.000 title description 8
- 241000196324 Embryophyta Species 0.000 claims abstract description 89
- 239000000203 mixture Substances 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 62
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 42
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 23
- 230000006378 damage Effects 0.000 claims abstract description 15
- 230000032683 aging Effects 0.000 claims abstract description 3
- 229930003827 cannabinoid Natural products 0.000 claims description 47
- 239000003557 cannabinoid Substances 0.000 claims description 47
- 229940065144 cannabinoids Drugs 0.000 claims description 31
- 208000014674 injury Diseases 0.000 claims description 15
- 208000027418 Wounds and injury Diseases 0.000 claims description 14
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 13
- 239000007921 spray Substances 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 9
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 230000004968 inflammatory condition Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000006199 nebulizer Substances 0.000 claims description 5
- 230000003190 augmentative effect Effects 0.000 claims description 4
- 238000011275 oncology therapy Methods 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000007922 nasal spray Substances 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 1
- 235000005607 chanvre indien Nutrition 0.000 abstract description 54
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 abstract description 53
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 abstract description 53
- 235000009120 camo Nutrition 0.000 abstract description 53
- 239000011487 hemp Substances 0.000 abstract description 53
- 206010028980 Neoplasm Diseases 0.000 abstract description 40
- 210000004556 brain Anatomy 0.000 abstract description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 22
- 201000011510 cancer Diseases 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 13
- 230000001225 therapeutic effect Effects 0.000 abstract description 12
- 238000002955 isolation Methods 0.000 abstract description 6
- 230000007850 degeneration Effects 0.000 abstract description 2
- 239000013598 vector Substances 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 240000004308 marijuana Species 0.000 description 60
- 210000004027 cell Anatomy 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 29
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 29
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 208000005017 glioblastoma Diseases 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 208000032612 Glial tumor Diseases 0.000 description 9
- 206010018338 Glioma Diseases 0.000 description 9
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 9
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 229960004242 dronabinol Drugs 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 7
- 239000000227 bioadhesive Substances 0.000 description 7
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 7
- 229950011318 cannabidiol Drugs 0.000 description 7
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- -1 cannabigerolovarin Chemical compound 0.000 description 6
- 239000000356 contaminant Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000001178 neural stem cell Anatomy 0.000 description 6
- 239000000232 Lipid Bilayer Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000002716 delivery method Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 4
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 210000001808 exosome Anatomy 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000001348 anti-glioma Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000001325 log-rank test Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 210000002706 plastid Anatomy 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- IQSYWEWTWDEVNO-ZIAGYGMSSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCC)C(C(O)=O)=C1O IQSYWEWTWDEVNO-ZIAGYGMSSA-N 0.000 description 2
- KXKOBIRSQLNUPS-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid Chemical compound O1C(C)(C)C2=CC=C(C)C=C2C2=C1C=C(CCCCC)C(C(O)=O)=C2O KXKOBIRSQLNUPS-UHFFFAOYSA-N 0.000 description 2
- 235000011624 Agave sisalana Nutrition 0.000 description 2
- 244000198134 Agave sisalana Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000014461 Ataxins Human genes 0.000 description 2
- 108010078286 Ataxins Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 206010010254 Concussion Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 208000026072 Motor neurone disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000005890 Spectrin Human genes 0.000 description 2
- 108010019965 Spectrin Proteins 0.000 description 2
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HRHJHXJQMNWQTF-UHFFFAOYSA-N cannabichromenic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCCCC)C(C(O)=O)=C2O HRHJHXJQMNWQTF-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000001085 differential centrifugation Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000009527 percussion Methods 0.000 description 2
- 239000008251 pharmaceutical emulsion Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 1
- YCBKSSAWEUDACY-UHFFFAOYSA-N 11-hydroxy-thc Chemical compound C1=C(CO)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 YCBKSSAWEUDACY-UHFFFAOYSA-N 0.000 description 1
- CZXWOKHVLNYAHI-LSDHHAIUSA-N 2,4-dihydroxy-3-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-propylbenzoic acid Chemical compound OC1=C(C(O)=O)C(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 CZXWOKHVLNYAHI-LSDHHAIUSA-N 0.000 description 1
- FAVCTJGKHFHFHJ-GXDHUFHOSA-N 3-[(2e)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-propylbenzoic acid Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O FAVCTJGKHFHFHJ-GXDHUFHOSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 1
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 1
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 1
- SEEZIOZEUUMJME-VBKFSLOCSA-N Cannabigerolic acid Natural products CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 description 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- ZLHQMHUXJUPEHK-UHFFFAOYSA-N Cannabivarin Natural products CCCc1cc(O)c2c(OC(C)(C)c3ccccc23)c1 ZLHQMHUXJUPEHK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 1
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 1
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920002807 Thiomer Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000003349 alamar blue assay Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 1
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 description 1
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 description 1
- 229960003453 cannabinol Drugs 0.000 description 1
- 229930191614 cannabinolic acid Natural products 0.000 description 1
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000000745 plant chromosome Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
Abstract
Disclosed is a method and composition for using plant extracellular vesicles (EVs) as vectors for delivering therapeutic molecules to the CNS. We demonstrated that plant EVs are more efficient vectors than delivery with other methods. These vectors can used to treat diseases in the CNS, such as cancer, injuries like TBI, degeneration such as Alzheimer's and aging and cognitive disorders such as PTSD, depression and anxiety. New data using hemp derived EVs to treat cancers in the brain and to impact precursor cells in the brain and isolation of EVs are included. In addition, disclosed is an improvement on the efficacy of intra-nasal delivery and oral delivery when using EVs.
Description
CANNABIS PLANT DERIVED EXTRACELLULAR VESICLES AND THERAPEUTIC
METHODS USING THE SAME
BACKGROUND
Cannabinoids have long been used for their remedy of different ailments such as pain, seizures, cancer chemotherapy associated symptoms such as nausea and vomiting, and also for their direct anti-cancer effects by inducing cell death in tumor cells. The main cannabinoids that have been used extensively are delta 9-tetrahydroxicannabinol (THC) and cannabidiol (CBD).
These cannabinoids are extracted, purified and decarboxylated from different cannabis plant cultivars containing different cannabinoids at different ratios in raw acidic forms. While a lot of studies have been performed using decarboxylated cannabinoids, the scientific community has begun to appreciate therapeutic effects of cannabinoids in their acidic form such as the anti-tumor activity of cannabidiolic acid (CBD-A) and neuroprotective effects of tetrahydroxicannabinolic acid (THC-A).
Cannabinoids not only are limited in therapeutic applications by the types of cannabinoids being used but also by their delivery methods; oral, oro-mucusal, transdermal and intratumoral administration, each with its unique advantages and disadvantages. For therapy purpose in the central nervous system, in particular for brain tumors, to reach therapeutic concentrations (in brain tumor bed), patients are required to consume relatively high doses of cannabinoids orally on a daily basis. This is challenging for several reasons:
1- If cannabinoids are taken orally, they undergo extensive hepatic first-pass metabolism which reduces their plasma concentration and increases the psychoactive metabolites, 11-hydroxy THC, when THC
is administered. 2- Oral administration results in a systemic distribution in the body and in the long term, their accumulation in well-vascularized and fatty organs due to the lipophilic property of cannabinoids. 3- systemic distribution and accumulation have adverse effects on cardiovascular, renal and hepatic function particularly in elderly people with background diseases. Moreover, administration of low doses to avoid psychoactive effects of THC may result in a suboptimal concentration in the tumor bed that may increase tumor proliferation. To avoid these problems in CNS tumor therapy, cannabinoids may be delivered intratumorally, which is invasive and traumatic. In addition, despite delivering a high concentration of the cannabinoids to the tumor core in the latter approach, an adequate amount may not reach tumor locations far from the infusion site, which in turn may result in poor therapeutic outcomes.
BRIEF DESCRIPTION OF THE DRAWINGS
The present embodiments are illustrated by way of example, and not by way of limitation, in the figures of the accompanying drawings.
The following figures are illustrative only, and are not intended to be limiting Figure 1 shows hemp EVs characterization: A) EVs size distribution as determined by NTA. B) TEM picture of hemp EVs. C) Major cannabinoid content of hemp EVs based on LC-MS/MS analysis.
Figure 2 shows tumor cells (Human GBM LO) staining with free SYTOTM
RNASelectTM dye (A) versus uptaking SYTOTM RNASelectTM stained hemp EVs (B) after 3 hours of incubation.
Figure 3 shows In vitro anti- proliferative [at different concentrations, 7 days] effects of hemp EVs on A) mouse KR158 vs (B) human LO GBM lines and (C) and anti-migration [at 1pM
for 24 hours] effects of hemp NPs on human LO GBM line in culture. *P<0.05, **P=0.001, 0001.
Figure 4 shows intranasal delivery of SYTOTM RNASelectTM stained hemp NPs into a mouse brain. 1 & 2 are respectively showing hemp NPs distribution in tumor [1]
vs non-tumor
METHODS USING THE SAME
BACKGROUND
Cannabinoids have long been used for their remedy of different ailments such as pain, seizures, cancer chemotherapy associated symptoms such as nausea and vomiting, and also for their direct anti-cancer effects by inducing cell death in tumor cells. The main cannabinoids that have been used extensively are delta 9-tetrahydroxicannabinol (THC) and cannabidiol (CBD).
These cannabinoids are extracted, purified and decarboxylated from different cannabis plant cultivars containing different cannabinoids at different ratios in raw acidic forms. While a lot of studies have been performed using decarboxylated cannabinoids, the scientific community has begun to appreciate therapeutic effects of cannabinoids in their acidic form such as the anti-tumor activity of cannabidiolic acid (CBD-A) and neuroprotective effects of tetrahydroxicannabinolic acid (THC-A).
Cannabinoids not only are limited in therapeutic applications by the types of cannabinoids being used but also by their delivery methods; oral, oro-mucusal, transdermal and intratumoral administration, each with its unique advantages and disadvantages. For therapy purpose in the central nervous system, in particular for brain tumors, to reach therapeutic concentrations (in brain tumor bed), patients are required to consume relatively high doses of cannabinoids orally on a daily basis. This is challenging for several reasons:
1- If cannabinoids are taken orally, they undergo extensive hepatic first-pass metabolism which reduces their plasma concentration and increases the psychoactive metabolites, 11-hydroxy THC, when THC
is administered. 2- Oral administration results in a systemic distribution in the body and in the long term, their accumulation in well-vascularized and fatty organs due to the lipophilic property of cannabinoids. 3- systemic distribution and accumulation have adverse effects on cardiovascular, renal and hepatic function particularly in elderly people with background diseases. Moreover, administration of low doses to avoid psychoactive effects of THC may result in a suboptimal concentration in the tumor bed that may increase tumor proliferation. To avoid these problems in CNS tumor therapy, cannabinoids may be delivered intratumorally, which is invasive and traumatic. In addition, despite delivering a high concentration of the cannabinoids to the tumor core in the latter approach, an adequate amount may not reach tumor locations far from the infusion site, which in turn may result in poor therapeutic outcomes.
BRIEF DESCRIPTION OF THE DRAWINGS
The present embodiments are illustrated by way of example, and not by way of limitation, in the figures of the accompanying drawings.
The following figures are illustrative only, and are not intended to be limiting Figure 1 shows hemp EVs characterization: A) EVs size distribution as determined by NTA. B) TEM picture of hemp EVs. C) Major cannabinoid content of hemp EVs based on LC-MS/MS analysis.
Figure 2 shows tumor cells (Human GBM LO) staining with free SYTOTM
RNASelectTM dye (A) versus uptaking SYTOTM RNASelectTM stained hemp EVs (B) after 3 hours of incubation.
Figure 3 shows In vitro anti- proliferative [at different concentrations, 7 days] effects of hemp EVs on A) mouse KR158 vs (B) human LO GBM lines and (C) and anti-migration [at 1pM
for 24 hours] effects of hemp NPs on human LO GBM line in culture. *P<0.05, **P=0.001, 0001.
Figure 4 shows intranasal delivery of SYTOTM RNASelectTM stained hemp NPs into a mouse brain. 1 & 2 are respectively showing hemp NPs distribution in tumor [1]
vs non-tumor
[2] areas of a coronal brain section.
Figure 5 shows microglial cell Iba-limmunostaining in control (A) vs hemp NPs treated (B) mouse brain. Hemp NP treatment changes the morphology and density of microelial cells in the brain.
Figure 6 shows the effect of hemp NPs treatment on survival pf KR158 glioma-bearing mice. Hemp NPs treatment increased median survival (Log-rank test, "P=0.0016, 31 days [control] vs 42 days [Hemp NPs]).
Figure 5 shows microglial cell Iba-limmunostaining in control (A) vs hemp NPs treated (B) mouse brain. Hemp NP treatment changes the morphology and density of microelial cells in the brain.
Figure 6 shows the effect of hemp NPs treatment on survival pf KR158 glioma-bearing mice. Hemp NPs treatment increased median survival (Log-rank test, "P=0.0016, 31 days [control] vs 42 days [Hemp NPs]).
3 Figure 7 shows that hemp NPs treatment leads to accumulation of substantial amount of CBD-A and CBG-A in brain tissue.
Figure 8 shows that hemp NPs treatment leads to accumulation of substantial amount of CBD-A and CBG-A in brain tumor tissue.
Figure 9 shows that plant derived extracellular vesicles [EVs] improve intranasal delivery by 5-fold.
Figure 10 shows that plant derived extracellular vesicles [EVs] improves oral delivery of drugs to the CNS.
Figure 11 shows how plant derived EVs reduce inflammation in a TBI model.
Figure 12 shows that IBA-1 expression levels are reduced in EV treated animals following TBI.
Figure 13 shows how plant EVs target the Glioma progenitor and glioma stem cells.
Figure 14 shows that hemp EVs differentially modulate Neural Stem Cell [NSC]
and progenitor cell proliferation.
DETAILED DESCRIPTION
While modulating the total amount of each constituent cannabinoid such as THC
in drug formulations can improve on the breadth and effectiveness of these anti-glioma compounds, nano-packaging of cannabinoids, using acidic cannabinoids and employing targeted, local and noninvasive CNS delivery methods such as intranasal route are attractive translational approaches for cancers and other diseases of the CNS. These strategies reduce the overall administered dose of cannabinoids and their undesirable side effects, while maintaining or even enhancing cannabinoids effects on CNS disorders and anti-tumor efficacy.
In one embodiment, there is provided a method for treating brain cancer in a subject comprising administering plant extracellular vesicles (PEVs) containing one or more cannabinoids (CPEVs) to the subject wherein the CPEVs are delivered to the brain of the subject.
For example, methods described herein may be used for the treatment of glioblastoma. In certain aspects, the brain cancer is treated by administration of the PEVs intranasally, or alternatively parenterally. Delivery of the CPEVs to the brain can result in brain concentrations that are higher than serum concentrations resulting from other modes of administration (e.g.
intravascular or oral administration) thereby allowing a dosage of cannabinoid containing CPEVs to be used which is effective to treat the brain cancer while not causing the aforementioned side effects commonly associated with cannabinoid administration in the subject.
In a second embodiment, provided is a method for treating neurodegenerative diseases by administering a therapeutically effective amount of CPEVs to the central nervous system of a subject. Examples of neurodegenerative diseases of the CNS treatable with the compositions described herein include, but are not limited to one or more of Alzheimer's disease. Parkinson's disease, Huntington's disease, motor neuron disease, spinocerebellar ataxia, and spinal muscular atrophy.
In a third embodiment, provided is a method for treat CNS injuries in a subject by administering a therapeutically effective amount CPEVs as described herein.
Examples of CNS
injuries by the methods disclosed herein include, but are not limited to as stroke, traumatic brain injury, concussion, spinal cord injury and the like.
In a fourth embodiment, provided is a method for reducing inflammatory conditions in the CNS of a subject by administering a therapeutically effective amount of CPEVs disclosed herein. Examples of inflammatory conditions treatable by the compositions described herein include auto-immune diseases (e.g. multiple sclerosis, encephalitis and the like).
In a fifth embodiment, provided is a method for augmenting function of the CNS
by administering an effective amount of CPEVs as disclosed herein. Augmenting function of the CNS includes, but is not limited to reducing aging of the brain, maintaining or enhancing cognitive function, motor function and/or resilience to injury and disease.
In a sixth embodiment, provided is a method for enhancing the oral delivery of molecules to the CNS using a therapeutically effective amount of CPEV. This delivery method can be used to treat a variety of CNS diseases, dysfunctions, reduce inflammation and augment CNS
function.
Figure 8 shows that hemp NPs treatment leads to accumulation of substantial amount of CBD-A and CBG-A in brain tumor tissue.
Figure 9 shows that plant derived extracellular vesicles [EVs] improve intranasal delivery by 5-fold.
Figure 10 shows that plant derived extracellular vesicles [EVs] improves oral delivery of drugs to the CNS.
Figure 11 shows how plant derived EVs reduce inflammation in a TBI model.
Figure 12 shows that IBA-1 expression levels are reduced in EV treated animals following TBI.
Figure 13 shows how plant EVs target the Glioma progenitor and glioma stem cells.
Figure 14 shows that hemp EVs differentially modulate Neural Stem Cell [NSC]
and progenitor cell proliferation.
DETAILED DESCRIPTION
While modulating the total amount of each constituent cannabinoid such as THC
in drug formulations can improve on the breadth and effectiveness of these anti-glioma compounds, nano-packaging of cannabinoids, using acidic cannabinoids and employing targeted, local and noninvasive CNS delivery methods such as intranasal route are attractive translational approaches for cancers and other diseases of the CNS. These strategies reduce the overall administered dose of cannabinoids and their undesirable side effects, while maintaining or even enhancing cannabinoids effects on CNS disorders and anti-tumor efficacy.
In one embodiment, there is provided a method for treating brain cancer in a subject comprising administering plant extracellular vesicles (PEVs) containing one or more cannabinoids (CPEVs) to the subject wherein the CPEVs are delivered to the brain of the subject.
For example, methods described herein may be used for the treatment of glioblastoma. In certain aspects, the brain cancer is treated by administration of the PEVs intranasally, or alternatively parenterally. Delivery of the CPEVs to the brain can result in brain concentrations that are higher than serum concentrations resulting from other modes of administration (e.g.
intravascular or oral administration) thereby allowing a dosage of cannabinoid containing CPEVs to be used which is effective to treat the brain cancer while not causing the aforementioned side effects commonly associated with cannabinoid administration in the subject.
In a second embodiment, provided is a method for treating neurodegenerative diseases by administering a therapeutically effective amount of CPEVs to the central nervous system of a subject. Examples of neurodegenerative diseases of the CNS treatable with the compositions described herein include, but are not limited to one or more of Alzheimer's disease. Parkinson's disease, Huntington's disease, motor neuron disease, spinocerebellar ataxia, and spinal muscular atrophy.
In a third embodiment, provided is a method for treat CNS injuries in a subject by administering a therapeutically effective amount CPEVs as described herein.
Examples of CNS
injuries by the methods disclosed herein include, but are not limited to as stroke, traumatic brain injury, concussion, spinal cord injury and the like.
In a fourth embodiment, provided is a method for reducing inflammatory conditions in the CNS of a subject by administering a therapeutically effective amount of CPEVs disclosed herein. Examples of inflammatory conditions treatable by the compositions described herein include auto-immune diseases (e.g. multiple sclerosis, encephalitis and the like).
In a fifth embodiment, provided is a method for augmenting function of the CNS
by administering an effective amount of CPEVs as disclosed herein. Augmenting function of the CNS includes, but is not limited to reducing aging of the brain, maintaining or enhancing cognitive function, motor function and/or resilience to injury and disease.
In a sixth embodiment, provided is a method for enhancing the oral delivery of molecules to the CNS using a therapeutically effective amount of CPEV. This delivery method can be used to treat a variety of CNS diseases, dysfunctions, reduce inflammation and augment CNS
function.
4 In some aspects, methods disclosed herein concern administration of composition comprising CPEVs to a subject such that the CPEVs are delivered to the brain of the subject. For instance, CPEVs can be administered intranasally or intracranially and, in various aspects, is administered 1, 2, 3, 4, 5 or more times. Intracranial administration of CPEVs is accomplished, in some aspects, by providing the CPEVs though a cannula. In certain other aspects, CPEVs provided in a liquid composition formulated for intranasal administration that typically includes an excipient for intranasal administration. Moreover, in some cases, intranasal administration of CPEVs is accomplished by applying pressure to an CPEV composition. Thus, in some cases, an CPEV composition for intranasal delivery is comprised in a syringe, a nebulizer, a respirator or a squeeze bottle such that pressure can be applied to facilitate CPEV delivery to the intranasal passages of the subject (e.g., via a mechanical action by a human or pump or via a compressed gas).
CPEVs may be provided in a variety of formulations any of which may be used for methods disclosed herein. In some cases, CPEV composition is formulated to enhance uptake to the brain from the intranasal passages.
In still further aspects, pharmaceutical compositions comprising CPEVs are provided. For example, in one aspect, the disclosure provides an CPEV composition for intracranial administration comprising CPEVs formulated in artificial cerebrospinal fluid (ACSF). Folmulations for ACSF are known in the art and certain specific formulations are detailed herein. Alternatively, there is provided, a pharmaceutical composition for intranasal administration comprising a dosage of CPEV effective to treat brain cancer (e.g.
glioblastoma) when administered to a subject via the intranasal route in a carrier formulated for intranasal administration. Moreover, in certain aspects, CPEV compositions are administered by a syringe, a nebulizer, a respirator (or a cartridge that is a designed for coupling to a nebulizer or respirator) or a squeeze bottle to facilitate intranasal administration. In still further aspects, CPEV compositions for intracranial or intranasal administration can comprise a second therapeutic agent such as, for example, a chemotherapeutic agent, an antiviral, an antibiotic or an anti-inflammatory agent. Other therapeutic agents may be added to the PEV
composition by exogenous delivery, using known methods, or by genetically modifying the plant material with the PEVs are isolated from.
CPEVs may be provided in a variety of formulations any of which may be used for methods disclosed herein. In some cases, CPEV composition is formulated to enhance uptake to the brain from the intranasal passages.
In still further aspects, pharmaceutical compositions comprising CPEVs are provided. For example, in one aspect, the disclosure provides an CPEV composition for intracranial administration comprising CPEVs formulated in artificial cerebrospinal fluid (ACSF). Folmulations for ACSF are known in the art and certain specific formulations are detailed herein. Alternatively, there is provided, a pharmaceutical composition for intranasal administration comprising a dosage of CPEV effective to treat brain cancer (e.g.
glioblastoma) when administered to a subject via the intranasal route in a carrier formulated for intranasal administration. Moreover, in certain aspects, CPEV compositions are administered by a syringe, a nebulizer, a respirator (or a cartridge that is a designed for coupling to a nebulizer or respirator) or a squeeze bottle to facilitate intranasal administration. In still further aspects, CPEV compositions for intracranial or intranasal administration can comprise a second therapeutic agent such as, for example, a chemotherapeutic agent, an antiviral, an antibiotic or an anti-inflammatory agent. Other therapeutic agents may be added to the PEV
composition by exogenous delivery, using known methods, or by genetically modifying the plant material with the PEVs are isolated from.
5 In yet further embodiments, the disclosure provides an intranasal CPEV
delivery system comprising CPEVs formulated for intranasal delivery and a pressure source sufficient to deliver the CPEV to the intranasal passages of a subject. In certain aspects, the pressure source is defined as supplying sufficient pressure to deliver an CPEV composition to the intranasal passages of a subject. For example, the pressure source may be a syringe, a nebulizer, a respirator a squeeze bottle or a pump. In certain aspects, a CPEV
delivery system comprises a single unit dosage of CPEV effective for addressing cancer, neurodegenerative diseases, inflammatory conditions, CNS injuries, or augmenting CNS function in a human subject. Thus, in still further aspects, there is provided a kit for the treatment of brain cancer, comprising one or more unit doses of CPEVs formulated for intranasal administration.
In additional embodiments, the disclosure provides uses of compositions described herein for the preparation of medicaments. For example, PEVs may be isolated from a plant such as hemp or other cannabis species, and engineered to include an exogenous payload. In such example, the PEVs are used a delivery vehicle for certain constituents and medicaments. Other related aspects are also provided in the instant invention.
The foregoing summary is not intended to define every aspect of the invention, and additional aspects are described in other sections, such as the following detailed description. The entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein arc contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document. Other features and advantages of the invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, because various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
Definitions Where the definition of terms departs from the commonly used meaning of the term, applicant intends to utilize the definitions provided below, unless specifically indicated.
delivery system comprising CPEVs formulated for intranasal delivery and a pressure source sufficient to deliver the CPEV to the intranasal passages of a subject. In certain aspects, the pressure source is defined as supplying sufficient pressure to deliver an CPEV composition to the intranasal passages of a subject. For example, the pressure source may be a syringe, a nebulizer, a respirator a squeeze bottle or a pump. In certain aspects, a CPEV
delivery system comprises a single unit dosage of CPEV effective for addressing cancer, neurodegenerative diseases, inflammatory conditions, CNS injuries, or augmenting CNS function in a human subject. Thus, in still further aspects, there is provided a kit for the treatment of brain cancer, comprising one or more unit doses of CPEVs formulated for intranasal administration.
In additional embodiments, the disclosure provides uses of compositions described herein for the preparation of medicaments. For example, PEVs may be isolated from a plant such as hemp or other cannabis species, and engineered to include an exogenous payload. In such example, the PEVs are used a delivery vehicle for certain constituents and medicaments. Other related aspects are also provided in the instant invention.
The foregoing summary is not intended to define every aspect of the invention, and additional aspects are described in other sections, such as the following detailed description. The entire document is intended to be related as a unified disclosure, and it should be understood that all combinations of features described herein arc contemplated, even if the combination of features are not found together in the same sentence, or paragraph, or section of this document. Other features and advantages of the invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, because various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
Definitions Where the definition of terms departs from the commonly used meaning of the term, applicant intends to utilize the definitions provided below, unless specifically indicated.
6 The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms "a,"
"an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise these terms do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. Furthermore, to the extent that the terms "including."
"includes," "having,"
"has," "with," or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term "comprising."
The term "about" or "approximately" is meant to denote up to a 5, 6, 7, 8, 9.
or 10 percent variance in the stated value or range. For example, about 2 includes values of 1.9 to 2.1.
As used herein, the term -adjunct cancer therapy protocol" refers to a therapy, such as surgery, chemotherapy, radiotherapy, thermotherapy, and laser therapy, and may provide a beneficial effect when administered in conjunction with administration As used herein, the term -an amount" refers to a statistically significant amount.
The term "cancer" as used herein means is intended to include any neoplastic growth in a patient, including an initial tumor and any metastases. The cancer can be of the liquid or solid tumor type. Liquid tumors include tumors of hematological origin (hematological cancer), including, e.g., myelomas (e.g., multiple myeloma), leukemias (e.g., Waldenstrom's syndrome, chronic lymphocytic leukemia, other leukemias), and lymphomas (e g, B-cell lymphomas, non-Hodgkins lymphoma). Solid tumors can originate in organs, and include cancers such as brain cancer (e.g. glioblastoma), or other solid tumors such as lung, breast, prostate, ovary, colon, kidney, and liver cancer.
The term "cancer cell" as used herein means a cell that shows aberrant cell growth, such as increased cell growth. A cancerous cell may be a hyperplastic cell, a cell that shows a lack of contact inhibition of growth in vitro, a tumor cell that is incapable of metastasis in vivo, or a metastatic cell that is capable of metastasis in vivo. A cancer cell also includes a cancer stem cell.
The term "cannabinoid" as used herein refers to an agent found in Cannabis sativa or Cannabis indica including tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THC
"an," and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise these terms do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. Furthermore, to the extent that the terms "including."
"includes," "having,"
"has," "with," or variants thereof are used in either the detailed description and/or the claims, such terms are intended to be inclusive in a manner similar to the term "comprising."
The term "about" or "approximately" is meant to denote up to a 5, 6, 7, 8, 9.
or 10 percent variance in the stated value or range. For example, about 2 includes values of 1.9 to 2.1.
As used herein, the term -adjunct cancer therapy protocol" refers to a therapy, such as surgery, chemotherapy, radiotherapy, thermotherapy, and laser therapy, and may provide a beneficial effect when administered in conjunction with administration As used herein, the term -an amount" refers to a statistically significant amount.
The term "cancer" as used herein means is intended to include any neoplastic growth in a patient, including an initial tumor and any metastases. The cancer can be of the liquid or solid tumor type. Liquid tumors include tumors of hematological origin (hematological cancer), including, e.g., myelomas (e.g., multiple myeloma), leukemias (e.g., Waldenstrom's syndrome, chronic lymphocytic leukemia, other leukemias), and lymphomas (e g, B-cell lymphomas, non-Hodgkins lymphoma). Solid tumors can originate in organs, and include cancers such as brain cancer (e.g. glioblastoma), or other solid tumors such as lung, breast, prostate, ovary, colon, kidney, and liver cancer.
The term "cancer cell" as used herein means a cell that shows aberrant cell growth, such as increased cell growth. A cancerous cell may be a hyperplastic cell, a cell that shows a lack of contact inhibition of growth in vitro, a tumor cell that is incapable of metastasis in vivo, or a metastatic cell that is capable of metastasis in vivo. A cancer cell also includes a cancer stem cell.
The term "cannabinoid" as used herein refers to an agent found in Cannabis sativa or Cannabis indica including tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THC
7 Acid), cannabidiol (CBD), cannabidiolic acid (CBD Acid), cannabigerolic acid, cannabigerol, cannabigerovarinic acid, cannabigerolovarin, cannabichromenic acid, cannabichromene, cannabidivarin, cannabidivarinic acid, tetrahydrocannabivarinic acid, tetrahydrocannabivarin, cannabivarinic acid, cannabivarin, cannabinolic acid, cannabinol, and isomers thereof, and mixtures of two or more of the foregoing thereof.
The term "cannabinoid containing PEV(s)" or "CPEVs" as used herein refers to PEVs that contain one or more cannabinoids.
The term "co-administration" or "co-administering" as used herein refers to the administration of an active agent before, concurrently, or after the administration of another active agent such that the biological effects of either agents overlap. The combination of agents as taught herein can act synergistically to treat or prevent the various diseases, disorders or conditions described herein. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
As used herein, the term "concentrating" refers to a process whereby a molecule or structure of interest that is in a mixture that has been subjected to that process has a greater concentration after the process as compared to the concentration of the molecule in the mixture before the process.
As used herein, the term -enriching" (and -enriched" and the like) refers to a process whereby a molecule of interest or structure of interest that is in a mixture has an increased ratio of the amount of that molecule to the amount of other undesired components in that mixture after the enriching process as compared to before the enriching process.
"Excipient(s) for intranasal delivery" are described e.g. in US2013/0337067 and include pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HC1, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, and detergents (e.g. Tween 2OTM, Tween 8OTM, Pluronic F68TM, bile acid salts). The pharmaceutical composition can comprise pharmaceutically acceptable solubilizing agents (e.g. glycerol, polyethylene
The term "cannabinoid containing PEV(s)" or "CPEVs" as used herein refers to PEVs that contain one or more cannabinoids.
The term "co-administration" or "co-administering" as used herein refers to the administration of an active agent before, concurrently, or after the administration of another active agent such that the biological effects of either agents overlap. The combination of agents as taught herein can act synergistically to treat or prevent the various diseases, disorders or conditions described herein. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.
As used herein, the term "concentrating" refers to a process whereby a molecule or structure of interest that is in a mixture that has been subjected to that process has a greater concentration after the process as compared to the concentration of the molecule in the mixture before the process.
As used herein, the term -enriching" (and -enriched" and the like) refers to a process whereby a molecule of interest or structure of interest that is in a mixture has an increased ratio of the amount of that molecule to the amount of other undesired components in that mixture after the enriching process as compared to before the enriching process.
"Excipient(s) for intranasal delivery" are described e.g. in US2013/0337067 and include pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e.g., Tris-HC1, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, and detergents (e.g. Tween 2OTM, Tween 8OTM, Pluronic F68TM, bile acid salts). The pharmaceutical composition can comprise pharmaceutically acceptable solubilizing agents (e.g. glycerol, polyethylene
8 glycol), anti-oxidants (e.g. ascorbic acid, sodium metabisulfite), preservatives (e.g. thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g.
lactose, mannitol).
"Exogenous payload" refers to a payload loaded into PEVs that is from an external source, i.e., did not originate in the EVs. PEVs may contain a combination of both endogenous and exogenous payloads.
"Endogenous payload" refers to a payload that is naturally occurring in the PEVs. These would include PEVs that are isolated from genetically engineered and non-genetically engineered plants.
As used herein, the term -formulated for delivery to an animal" refers to a PEV
composition that includes a pharmaceutically acceptable carrier. As used herein, a "pharmaceutically acceptable" carrier or excipient is one that is suitable for administration to an animal (e.g., human), e.g., without undue adverse side effects to the animal (e.g., human).
"intranasal delivery" refers to extra- and transcellular transport through the olfactory and respiratory mucosal epithelium from the nasal cavity to the brain. This physiological process is described in detail in Van Woensel et al. (2013), cited above. Devices for intranasal delivery are commercially available and are known under the trade names Vianase (Kurve Technologies, USA) DirectHaler (Denmark) or OptiMist (Norway).
As used herein, the term "isolating," or "to isolate," refers to any artificial (i.e., not naturally occurring) process for treating a starting material, where the process results in a more useful form of a molecule or structure of interest (e.g. extracellular vesicles) that is in the starting material. The "more useful form" of the molecule or structure of interest can be characterized in a variety of ways, no one of which is limiting. For example, as used herein, certain embodiments provide methods for isolating extracellular vesicles from a cannabis plant or cells thereof.
Further, for example, the process for isolating can result in:
(i) the molecule of interest or structure of interest having a greater concentration in the isolated form compared to the starting material (e.g., concentrating),
lactose, mannitol).
"Exogenous payload" refers to a payload loaded into PEVs that is from an external source, i.e., did not originate in the EVs. PEVs may contain a combination of both endogenous and exogenous payloads.
"Endogenous payload" refers to a payload that is naturally occurring in the PEVs. These would include PEVs that are isolated from genetically engineered and non-genetically engineered plants.
As used herein, the term -formulated for delivery to an animal" refers to a PEV
composition that includes a pharmaceutically acceptable carrier. As used herein, a "pharmaceutically acceptable" carrier or excipient is one that is suitable for administration to an animal (e.g., human), e.g., without undue adverse side effects to the animal (e.g., human).
"intranasal delivery" refers to extra- and transcellular transport through the olfactory and respiratory mucosal epithelium from the nasal cavity to the brain. This physiological process is described in detail in Van Woensel et al. (2013), cited above. Devices for intranasal delivery are commercially available and are known under the trade names Vianase (Kurve Technologies, USA) DirectHaler (Denmark) or OptiMist (Norway).
As used herein, the term "isolating," or "to isolate," refers to any artificial (i.e., not naturally occurring) process for treating a starting material, where the process results in a more useful form of a molecule or structure of interest (e.g. extracellular vesicles) that is in the starting material. The "more useful form" of the molecule or structure of interest can be characterized in a variety of ways, no one of which is limiting. For example, as used herein, certain embodiments provide methods for isolating extracellular vesicles from a cannabis plant or cells thereof.
Further, for example, the process for isolating can result in:
(i) the molecule of interest or structure of interest having a greater concentration in the isolated form compared to the starting material (e.g., concentrating),
9 (ii) the removal of any amount or any type of impurities from the starting material (e.g., purifying), (iii) an increase in the ratio of the amount of molecule of interest or structure of interest to the amount of any undesired component in the starting material (e.g., enriching), (iv) any artificial process for removing a molecule or structure of interest from its natural source or location;
(v) any artificial process for separating a molecule or structure of interest from at least one other component with which it is normally associated (e.g., purifying). or (vi) any combination of (i), (ii), (iii), (iv) or (v).
Similarly, as used herein, the term "isolated" generally refers to the state of the molecule or structure of interest after the starting material has been subjected to a method for isolating the molecule of interest. That is to say, isolating a molecule of interest or structure of interest from a starting material will produce an isolated molecule. For example, the methods of the invention are used to produce preparations of isolated extracellular vesicles.
The term "neurodegenerative disease" as used herein refers to a condition that involve degeneration of neurons in the CNS system. Examples of neurodegenerative diseases include, but are not limited to, one or more of Alzheimer's disease, Parkinson' s disease, Huntington' s disease, motor neuron disease, spinocerebellar ataxia, and spinal muscular atrophy.
The term "CNS injuries" as used herein refers to injury or trauma to the CNS
of a subject.
Examples of CNS injuries include, but are not limited to one or more of stroke, traumatic brain injury, concussion, and spinal cord injury.
The term "inflammatory condition" as used herein refers to refers to any inflammatory disease or disorder known in the art whether of a chronic or acute nature.
Examples of inflammatory conditions treatable by the compositions described herein include auto-immune diseases (e.g. multiple sclerosis, encephalitis and the like.
The term "payload" as used with respect to PEVs refers to constituents contained by individual extracellular vesicles. In various embodiments, the extracellular vesicle membrane comprises an interior surface and an exterior surface and encloses an internal space. In certain embodiments, the payload is enclosed within the internal space. In other embodiments, the payload is displayed on the external surface of the extracellular vesicle. In other embodiments, the payload spans the membrane of the extracellular vesicle. In various embodiments, the payload comprises nucleic acids, proteins, carbohydrates, lipids, small molecules, and/or combinations thereof. The PEVs may contain both exogenous and/or endogenous payloads.
Further, endogenous payloads can be enriched above that which is found in nature. Payloads for loading into PEVs (i.e. exogenous payloads) may include a select therapeutic agent that are artificially chemical synthesized and/or isolated from other sources, including other plant or fungal material.
The term -PEV composition" refers to a PEVs combined with a carrier.
As used herein, the term "plant" refers to whole plants (e.g., whole seedlings or whole adult plants), plant organs, plant parts, plant tissues, seeds, plant cells, seeds, and progeny of the same.
As used herein, the term -plant extracellular vesicle" or -PEV" refers to a lipid structure (e.g., a lipid bilayer, unilamellar, multilamellar structure; e.g., a vesicular lipid structure), that is about 5-2000 nm (e.g., at least 5-1000 nm, at least 5-500 nm. at least 400-500 nm, at least 25-250 nm, at least 50-150 nm, or at least 70-120 nm) in diameter that is derived from (e.g., enriched, isolated or purified from) a plant source or segment, portion, or extract thereof, including lipid or non-lipid components (e.g., peptides, nucleic acids, or small molecules) associated therewith and that has been enriched, isolated or purified from a plant, a plant part, or a plant cell or from a culture medium in which a plant, plant part, or plant cell has been cultured (e.g., a culture medium of a plant cell culture or a hydroponic culture, e.g., secreted PEVs), the enrichment or isolation removing one or more contaminants or undesired components originating from the source plant, plant part, or plant cell or from the culture medium. In some examples, the isolation comprises removing an intact plant or plant part from the culture medium (e.g., a culture medium of a hydroponic system), e.g., removing the plant or plant part without disrupting (e.g., physically damaging) the plant or plant part. PEVs may be highly purified preparations of naturally occurring EVs. Preferably, at least 1 % of contaminants or undesired components from the source plant are removed (e.g., at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 70%, 80%, 90%, 95%, 96%, 98%, 99%, or 100%) of one or more contaminants or undesired components from the source plant, e.g., plant cell wall components; pectin; plant organelles (e.g., mitochondria; plastids such as chloroplasts, leucoplasts or amyloplasts; and nuclei); plant chromatin (e.g., a plant chromosome); or plant molecular aggregates (e.g., protein aggregates, nucleic acids, proteins, protein-nucleic acid aggregates, lipoprotein aggregates, lipido-proteic structures, or sugars). Preferably, a PEV is at least 30% pure (e.g., at least 40%
pure, at least 50% pure, at least 60% pure. at least 70% pure, at least 80%
pure, at least 90%
pure, at least 99% pure, or 100% pure) relative to the one or more contaminants or undesired components from the source plant as measured by weight (w/w), spectral imaging (%
transmittance), or conductivity (S/m). PEVs may encompass exosomes or microvesicles.
Generally, PEVs comprise a payload that can be delivered to a cell upon association of the PEV
with the cell. Exemplified herein are PEVs obtained from plant material of a Cannabis spp plant. As used herein, csPEV refers to a PEV from a Cannabis spp.
CPEVs may optionally include additional agents, such as heterologous functional agents, e.g., therapeutic agents, polynucleotides, polypeptides, or small molecules.
The CPEVs can carry or associate with additional agents (e.g., heterologous functional agents) in a variety of ways to enable delivery of the agent to a target plant, e.g., by encapsulation of the agent, incorporation of the agent in the lipid bilayer structure, or association of the agent (e.g., by conjugation) with the surface of the lipid bilayer structure. Exogenous functional agents can be incorporated into the CPEVs either in vivo (e.g., in planta) or in vitro (e.g., in tissue culture, in cell culture, or synthetically incorporated).
As used herein, the terms "purified" or "partially purified" refers to molecules or structures of interest that are removed from either (1) their natural environment, or from (2) a starting material (i.e., they are isolated), and where (a) at least one impurity from the starting material has been removed, or (b) at least one component with which the molecule is naturally associated has been removed. A "purified" or "partially purified" molecule may still contain additional components that may render future use or study of the molecule sub-optimal, difficult or impossible.
As used herein, the term -purifying" or "to purify" a molecule or structure of interest refers to a process for removing at least one impurity or contaminant from a starting material.
For example, purifying a molecule of interest from a starting material refers to a process for removing at least one impurity from the starting material to produce a relatively more pure form of the molecule of interest.
In a certain embodiment, a CPEV composition of this disclosure can be administered to a subject who has symptoms of or is diagnosed with a cancer. A composition of this invention can be administered prophylactically, i.e., before development of any symptom or manifestation of the disease, disorder or condition. Typically, in this case the subject will be at risk of developing the condition. Treating also may comprise treating a subject exhibiting symptoms of a certain disease, disorder or condition.
As used herein, the term "subject" refers to an animal being treated with CPEVs as taught herein. The term includes any animal, preferably a mammal, including, but not limited to, farm animals, zoo animals, companion animals, service animals, laboratory or experimental model animals, sport animals. More specific examples include simians, avians, felines, canines, equines, rodents, bovines, porcines, ovines, and caprines. The term specifically includes humans and human patients. In a specific embodiment, subjects pertain to human cancer patients or humans in need of treatment for cancer, including glioblastoma. A suitable subject for the invention can be any animal, preferably a human, that is suspected of having, has been diagnosed as having, or is at risk of developing a disease that can be ameliorated, treated or prevented by administration of one or more CPEVs. Therefore, a "subject in need" refers to a subject as defined herein that is suspected of having, has been diagnosed as having, or is at risk of developing a disease that can be ameliorated, treated or prevented by administration of one or more CPEVs and compositions including same.
As used herein, the term "substantially purified" refers to molecules or structures of interest that are removed from their natural environment or from a starting material (i.e., they are isolated) and where they are largely free from other components with which they are naturally associated or substantially free of other components that may render future use or study sub-optimal, difficult or impossible.
A "therapeutically effective amount" refers to an amount which, when administered in a proper dosing regimen, is sufficient to reduce or ameliorate the severity, duration, or progression of the disorder being treated (e.g., cancer), prevent the advancement of the disorder being treated (e.g., cancer), cause the regression of the disorder being treated (e.g., cancer), or enhance or improve the prophylactic or therapeutic effects(s) of another therapy. The full therapeutic effect does not necessarily occur by administration of one dose and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations per day for successive days.
The terms "treat", "treating" or "treatment of' as used herein refers to providing any type of medical management to a subject. Treating includes, but is not limited to, administering a composition to a subject using any known method for purposes such as curing, reversing, alleviating, reducing the severity of, inhibiting the progression of, or reducing the likelihood of a disease, disorder, or condition or one or more symptoms or manifestations of a disease, disorder or condition.
Plant Extracellular Vesicles A plant extracellular vesicle including exosomes, are nanoscale membrane-enclosed particles implicated in intercellular communication to facilitate transport of proteins and genetic material. Plant extracellular vesicles can have, but not be limited to, a diameter of greater than about about 5-2000 nm (e.g., at least 5-1000 nm, at least 5-500 nm, at least 400-500 nm, at least 25-250 nm, at least 50-150 nm, or at least 70-120 nm).
As used herein, plant extracellular vesicles can also include any shed membrane bound particle that is derived from either the plasma membrane or an internal membrane. Plant extracellular vesicles can also include cell-derived structures bounded by a lipid bilayer membrane arising from both herniated evagination (blebbing) separation and sealing of portions of the plasma membrane or from the export of any intracellular membrane-bounded vesicular structure containing various membrane-associated proteins. Plant extracellular vesicles can also include membrane fragments.
Plant extracellular vesicles can be directly assayed from the biological samples, such that the level of plant extracellular vesicles is determined or the one or more biomarkers of the plant extracellular vesicles are determined without prior isolation, purification, or concentration of the plant extracellular vesicles. Alternatively, plant extracellular vesicles may be isolated, purified, or concentrated from a sample prior to analysis.
Analysis of a plant extracellular vesicle can include quantitating the amount one or more plant extracellular vesicle populations of a biological sample. For example, a heterogeneous population of plant extracellular vesicles can be quantitated, or a homogeneous population of plant extracellular vesicles, such as a population of plant extracellular vesicles with a particular biomarker profile, a particular bio-signature, or derived from a particular cell type (cell-of-origin specific plant extracellular vesicles) can be isolated from a heterogeneous population of plant extracellular vesicles and quantitated. Analysis of a plant extracellular vesicle can also include detecting, quantitatively or qualitatively, a particular biomarker profile or a bio-signature, of a plant extracellular vesicle, as described below.
A plant extracellular vesicle can be stored and archived, such as in a bio-fluid bank and retrieved for analysis as necessary. A plant extracellular vesicle may also be isolated from a biological sample that has been previously harvested and stored from a living or deceased subject. In addition, a plant extracellular vesicle may be isolated from a biological sample or isolated from an archived or stored sample. Alternatively, a plant extracellular vesicle may he isolated from a biological sample and analyzed without storing or archiving of the sample.
Furthermore, a third party may obtain or store the biological sample, or obtain or store the plant extracellular vesicles for analysis.
An enriched population of plant extracellular vesicles can be obtained from a biological sample. For example, plant extracellular vesicles may be concentrated or isolated from a biological sample using size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof. These methods can be used to separate plant extracellular vesicles from contaminants.
Size exclusion chromatography, such as gel permeation columns, centrifugation or density gradient centrifugation, and filtration methods can be used. For example, plant extracellular vesicles can be isolated by differential centrifugation, anion exchange and/or gel permeation chromatography (for example, as described in U.S. Pat. Nos.
6,899,863 and 6,812,023), sucrose density gradients, organelle electrophoresis (for example, as described in U.S. Pat. No. 7,198,923), magnetic activated cell sorting (MACS), or with a nanomembrane ultrafiltration concentrator. Various combinations of isolation or concentration methods can be used.
Isolation or enrichment of plant extracellular vesicles from biological samples can also be enhanced by use of sonication (for example, by applying ultrasound), or the use of detergents, other membrane- active agents, or any combination thereof.
Administration In some embodiments, the composition embodiments comprising CPEVs described herein will be administered intranasally to a mammalian subject in need thereof using a level of pharmaceutical composition that is sufficient to provide the desired physiological effect. The mammalian subject may be a domestic animal or pet but preferably is a human subject. The level of pharmaceutical composition needed to give the desired physiological result is readily determined by one of ordinary skill in the art. Other parameters that may be taken into account in determining dosage for the pharmaceutical composition embodiments described herein may include disease state of the subject or age of the subject. The composition will typically include an excipient for intranasal delivery.
The compositions may take the form of suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. In some embodiments, the composition embodiments described herein may be administered orally or intravenously (e.g. via parenteral nutritional therapy) to a subject via an emulsion. The emulsion may include, in some embodiments, an aqueous continuous phase and a dispersed phase. The boundary between the phases called the "interface". The present emulsions are adapted for application to a mucosal surface of a vertebrate animal, preferably a mammal, including humans. These compositions improve the permeability and bioavailability of active compounds after application to a mucous surface. Mucosal surfaces of interest include the intestinal mucosa. Use of bioadhesive polymers in pharmaceutical emulsions affords enhanced delivery of drugs in bioadhesive polymer-coated suspensions, in some examples.
Bioadhesive pharmaceutical emulsions may be used to deliver the described herein to: a) prolong the residence time in situ, thereby decreasing the number of drug administrations required per day;
and b) may be localized in the specified region to improve and enhance targeting and bioavailability of delivered drugs.
The ability to retain and localize a CPEV delivery emulsion in a selected region leads to improved bioavailability, especially for drugs exhibiting a narrow window of adsorption due to rapid metabolic turnover or quick excretion. Intimate contact with the target absorption membrane improves both the extent and rate of drug absorption.
Bioadhesion is the characteristic of certain natural and synthetic polymers of binding to various biological tissues. Of particular interest are polymers which bind to the mucous lining that covers the surface of many tissues which communicate directly or indirectly with the external environment, such as the nasal mucosa, for example. Mucus binding polymers may be referred to as mucoadhesive. Several bioadhesive, and specifically mucoadhesive, polymers are known. The chemical properties of the main mucoadhesive polymers are summarized as follows:
a. strong H-bonding groups (--OH, --COOH) in relatively high concentration;
b. strong anionic charges;
c. sufficient flexibility of polymer backbone to penetrate the mucus network or tissue crevices;
d. surface tension characteristics suitable for wetting mucus and mucosal tissue surfaces;
and e. high molecular weight.
Bioadhesive polymers may be used in the pharmaceutical composition embodiments described herein, examples of bioadhesive polymers currently used in pharmaceutical preparations include: carboxymethylcellulose (CMC), hydroxypropylmethylcellulose (HPMC), polyacrylic and polymethacrylic acid and their derivatives, pectin, alginic acid, chitosan, polyvinylpyrrolidone, hyaluronic acid, and polyvinyl alcohol. The most frequently used polymer is Carbopol (Carbomer), which is a high molecular weight polyacrylic acid polymer. It is used in many formulations for bioadhesive drug delivery systems, as a suspending agent, as a tablet coating, and in ocular suspensions.
Pharmaceutical composition embodiments described herein may include the composition comprising PEVs, CPEVs or csPEVs incorporated into inert lipid carriers such as oils, surfactant dispersions, emulsions, liposomes etc. Self-emulsifying formulations are ideally isotropic mixtures of oils, surfactants and co-solvents that emulsify to form fine oil in water emulsions when introduced in aqueous media. Fine oil droplets would pass rapidly from stomach and promote wide distribution of drug throughout the GI tract, thereby overcome the slow dissolution step typically observed with solid dosage forms. These embodiments may provide control release self-emulsifying pellets, microspheres, tablets, capsules etc. that increase the use of "self-emulsification."
Intranasal delivery is the typical mode of administration to deliver the PEVs, CPEVs or csPEVs to a subject in need. However, in alternative embodiments, other methods of administration are contemplated. Accordingly, suitable methods for administering a PEV, CPEV
or csPEV containing composition in accordance with the methods of the presently-disclosed subject matter include, but arc not limited to, oral administration, systemic administration, parenteral administration (including intravascular, intramuscular, and/or intraarterial administration), oral delivery, buccal delivery, rectal delivery, subcutaneous administration, intraperitoneal administration, inhalation, dermally (e.g., topical application), intratracheal installation, surgical implantation, transdermal delivery, local injection, and hyper-velocity injection/bombardment. Where applicable, continuous infusion can enhance drug accumulation at a target site (see, e.g., U.S. Pat. No. 6,180,082). In some embodiments of the therapeutic methods described herein, the therapeutic compositions are administered orally, intravenously, intranasally, or intraperitoneally to thereby treat a disease or disorder.
Regardless of the route of administration, the compositions of the presently-disclosed subject matter typically not only include an effective amount of a PEVs, but are typically administered in amount effective to achieve the desired response. As such, the term "effective amount" is used herein to refer to an amount of the therapeutic composition (e.g., a PEVs and a pharmaceutically vehicle, carrier, or excipient) sufficient to produce a measurable biological response (e.g., reduction in cancer cells). Actual dosage levels of active ingredients in a therapeutic composition of the present invention can be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular subject and/or application. Of course, the effective amount in any particular case will depend upon a variety of factors including the activity of the therapeutic composition, formulation, the route of administration, combination with other drugs or treatments, severity of the condition being treated, and the physical condition and prior medical history of the subject being treated. Preferably, a minimal dose is administered, and the dose is escalated in the absence of dose-limiting toxicity to a minimally effective amount.
Deteimination and adjustment of a therapeutically effective dose, as well as evaluation of when and how to make such adjustments, are known to those of ordinary skill in the art. Background information on formulations of extracellular vesicles and loading EVs with exogenous payloads is taught in U.S.
Patent No. 10,723,782, and Tran et al. "Exosomes as Nanocarriers for Immunotherapy of Cancer and Inflammatory Diseases. (2015) Clin Immunol. PMID: 25842185.
Kits In view of the new findings described herein that cannabinoids packaged in plant extracellular vesicles can improve delivery of cannabinoids to tissues or cells (tumor or normal cells), kits are provided that include a container for housing the PEVs and an applicator for delivery of the PEVs. In a specific example, the applicator includes a tapered spout for insertion into a nostril of a subject that attaches to the container. The CPEV
compositions described herein can be administered to the nasal cavity in any suitable form, for example in the form of drops or sprays.
Methods suitable for administering a CPEV or csPEV composition to the nasal cavity will be well known by the person of ordinary skill in the art. Any suitable method may be used.
The preferred method of administration is the use of a spray device. Spray devices can be single (unit) dose or multiple dose systems, for example comprising a bottle, pump and actuator, and are available from various commercial sources including Pfeiffer, Valois, Bespak and Becton-Dickinson. Electrostatic spray devices, such as described in U.S. Pat. No.
5,655,517, are also suitable for the intranasal administration of the compositions of the present invention.
For a spray device, the typical volume of liquid that is dispensed in a single spray actuation is in the range of from 0.01 to 0.15 ml. A typical dosing regimen for a nasal spray product would be in the range of one spray into a single nostril to two sprays into each nostril.
The present invention also provides a spray device loaded with a composition as defined above.
EXAMPLES
To this end, we have discovered and isolated naturally occurring hemp extracellular vesicles (EVs) that are enriched with a payload of cannabinoids in acidic forms. Floral parts of fresh hemp plant were juiced. Hemp juice was first centrifuged at different speeds (from 2000-35000 xg) and filtered through different size paper filters to remove debris and particles larger than 0.221aM and then was transferred to ultracentrifuge tubes and centrifuged at 150,000 xg for 1 hour in a Beckman Coulter OptimaTM XE ultracentrifuge with a Type 45 Ti rotor. The EV
pellet was resuspended in sterile PBS and stored in -80 C freezer.
Nanotracking analysis (NTA, Nanosight NS300 instrument) has shown that hemp EVs have a median diameter of 112.6 nm (Figure 1A). Transmission electron microscopy (TEM, Tecnai G2 F20-TWIN) evaluation has validated the size and morphology of hemp EVs with a lipid bilayer structure typical of the EVs (Figure 1B). Major cannabinoid content of hemp EVs (CBD, CBD-A, THC, THC-A, CBG, CBG-A) was quantified using Liquid chromatography tandem mass spectrometry (LC-MS/MS).
Analytes were extracted from the EVs using solid phase extraction (C18 cartridge) method. EV
samples were spiked with deuterated internal standards prior to the extraction to check recovery and correction of extraction efficiency. Our results have shown that CBD-A, CBG-A, THC-A, CBD, and THC represent 69.1 2.1%, 19.1 1.6%, 6.5 0.54%, 4.75 0.26%, and 0.5 0.3%
of the total cannabinoids in hemp EVs (Figure 1C) without any detectable level of CBG.
To assay the uptake of EVs by cells, we labelled hemp EVs with SYTOTM
RNASelectTM green fluorescent cell stain as per manufacturer's instructions and removed excess unincorporated dye from the labelled EVs with exosome spin columns (MW
3000).
Human glioblastoma tumor cells were plated in laminin coated coverslip in growth medium overnight and then the labeled EVs were added to each well and EVs uptake by the cells was assessed 3 hours later. Our results show that EVs can be taken up by GBM cells in vitro presenting a characteristic dotted staining pattern in contrast to a uniform cytoplasmic staining pattern of cells exposed to the free dye (Figure 2). In vitro anti-glioma effects of the hemp EVs were studied both in human and murine GBM cell lines. First, the mean CBD-A
concentration per EV and then the number of EVs equal to a certain CBD-A concentration was calculated based on the LC-MS/MS results. Tumor cells were plated in 96 wells in neurosphere growth medium supplemented with hemp EVs corresponding to different CBD-A
concentrations. After 7 days, the mean fluorescent intensity (as an index of cell proliferation) was measured and nonnalized based on that of the control condition using Alamar Blue assay.
Hemp EVs have shown significant anti-glioma effect starting at a number that is equivalent to or more than liaM
of CBD-A (Figure 3A,B). Overnight incubation of human GBM tumor cells with a non-killing dose of hemp EVs effectively reduces GBM cell migration in a transwell migration assay (Figure 3C). In order to test the intranasal delivery of hemp EVs, we used a C57/B16 mouse with an established KR-158 tumor in the left hemisphere and delivered 12ittl of SYTOTM
RNASelectTM
green fluorescent labelled hemp EVs in both nostrils ( 2 Onostril every 5 minutes).
The animal were sacrificed 24 hours later and brain tissue was fixed, cryosectioned and stained for anti-nestin antibody and counterstained with DAPI to distinguish the tumor vs non-tumor areas of the brain, labelled hemp EVs are scattered throughout the brain hemispheres (Figure 4).
To assay antitumor effect of hemp EVs, a cohort of animals were implanted with tumor. Three days after implantation, the animals were randomly placed in two groups receiving either PBS (vehicle of hemp EVs, control group) or hemp EVs every day intranasally for 35 days (twice daily with 6 hour interval between the two intranasal deliveries).
Immunofluorescence analysis of brain tissue for Iba-1 in control and hemp EV treated group showed a distinct difference in microglial cell morphology and density between the two groups (Figure 5 A,B).
Animal survival analysis using Log-rank test revealed that hemp EV therapy significantly increased animal survival and slowed down tumor growth (Figure 6). LC-MS/MS
analysis of cannabinoid content of the brain (Figure 7) and KR-158 tumor tissue (Figure 8) showed that intranasal hemp EV delivery leads to a substantial amount of CBD-A and CBG-A
in these tissues. This discovery is exciting because delivering hemp EVs with its natural cannabinoid payload directly into the brain via noninvasive intranasal approach will improve killing of malignant brain tumor cells, thereby increasing treatment response, improving patient survival and potentially achieving a cure. Intranasal delivery of cannabinoids in natural nanovesicle form holds a great promise circumventing the systemic effects of cannabinoid oral delivery and bypassing first pass metabolism in liver. Additionally, intranasal delivery method of cannabinoids represents a promising, safe and gentle alternative to the invasive, inconvenient and costly delivery methods such as intratumoral approach delivery approach for brain tumors. Hemp EVs have an endogenous payload of cannabinoids and the technology can rapidly move into clinical testing.
Cannabidiolic acid (CBDa) was dissolved in PBS (64 ng/lOul) or hemp EVs, isolated, and diluted to have the same CBDa concentration as purified CBDa. C57/B6 mice received a single dose (10 pl purified CBDa or 10p1 of hemp EVs) intranasally. One hour after treatment animals were killed, brains removed and CBDa content analyzed with Linear Ion Trap Quadrupole LC-MS/MS (AB SCIEX Instruments). CBDa levels in the brain were 5-fold higher when delivered with hemp EVs (Figure 9).
C57/B6 mice were gavaged with hemp derived EV containing approximately 6.411g of CBDa and 0.140pg THCa. One, 3,6 and 12 hours post gavage animals were killed, brains removed and CBDa and THCa content analyzed with Linear Ton Trap Quadrupole LC-MS/MS
[AB SCIEX Instruments]. Peak levels of CBDa and THCa were seen at 1 hour post gavage, with concentrations being 2.5 ng/mg and 0.06 ng/mg of brain tissue, respectively (Figure 10A). This can be compared to Anderson et al., 2019* who delivered by IP injection approximately 300iag of CBDa or THCa to C57/B6 mice, either dissolved in vegetable oil or in ethanol Tween-80 solution and analyzed plasma and brain levels of each compound (Figure 10B).
While THCa levels were below detection in the brain, CBDa demonstrated a Cmax at 30 mins with concentrations of 2.0 ng/mg and 13.2 ng/mg in vegetable oil or Tween-80, respectively.
Comparison between Anderson et al., 2019 and plant EV delivery (Figure 10C).
Percentage of CBDa or THCa in brain (ng/mg of tissue/dosage) for each method demonstrates the plant EV
have a 7.5 - 43 fold increase in CBDa brain penetration over Tween-80 or vegetable oil vehicles, respectively. THCa penetration with plant EVs were similar to CBDa.
TBI was induced using a unilateral fluid percussion injury (FPI) model and the animals were treated with either 10 1.11 of PBS or hemp EVs one hour after injury, twice daily for 7days.
Animals were bled at 24 hrs, 72 hrs and 7 days post-TBI and sacrificed on day 7. Western blot analysis of GFAP and Spectrin protein levels in the injured cortex of the control and plant EV
treated TBI animals (Figure 11A-B). A significant reduction in GFAP and Spectrin protein levels are seen in the plant EV treated TBI animals. Inflammatory cytokine analysis using (V-PLEX proinflammatory panel (Mesoscale Diagnostics)) at 24 hours, 72 hours and 7 days post injury reveal that plant EVs result in a significant increase in anti-inflammatory cytokines at 72 hours for IL-4 (Figure 11C) & IL-10 (Figure 11D).
TBI was induced using a unilateral fluid percussion injury (FPI) model and the animals were treated with either 10 1.11 of PBS or hemp EVs one hour after injury, twice daily for 7 days.
Animals were sacrificed on day 7 for brain histological analysis. Control brains IBA-11 (rabbit anti-IBA-1, Encor biotechnology) is upregulated in microglia signifying their activation (Figure 12A). EV treated animals demonstrate a qualitative reduction in IBA-1 microglia expression supporting the notion that plant EVs are able to attenuate inflammation and microglia activation following TBI (Figure 12B).
Plant EV increased survival of KR-1861uc glioma bearing mice. EV treatment increased median survival (log-rank test, from 31 to 42 days) (Figure 13).
After performing a dose-response analysis to determine the effective antiproliferative concentration (LD50) of the hemp EVs, glioma (mouse KR-158 and human LO) cells were plated in the neurosphere assay culture and treated with three doses of hemp EVs (number of EVs corresponding to their CBDa concentration) that were less than LD50. After 7 days in culture the number and size of neurospheres were determined in each condition. With increasing concentration of the hemp EVs, both the neurosphere forming frequency and neurosphere size decrease which together shows antiproliferative effect of the hemp EVs on glioma cells (Figure 14A). Using a mathematical model, serial passaging of the glioma cells in neurophere culture supplemented with an effective antiproliferative dose of the hemp EVs (1 ilM) have shown that hemp EVs significantly reduce symmetric cell division in glioma stem cells resulting in a significant decrease in glioma tumor cells expansion over time (Figure 14B).
Different hemp cultivars (B4 CBDa and Gold CBGa enriched) were used to isolated EVs, which were subsequently concentrated and delivered intranasally twice a day for 7 days. Animals were killed, subventricular zone micro-dissected, tissue dissociated and placed in the Neurosphere Assay. Seven to 10 days later the number of spheres and their diameter where quantitated. Sphere-fat __________________________________________________________ ming frequency is a reflection of the number of NSCs in vivo and was increased by the Gold EVs (Figure 15A). B4 cultivar, which is enriched in CBDa did not increase the number of NSCs while both Gold EVs, containing decarboxylated CBG
and the acidic form of CB G (CBGa), significantly increased the number of NSCs in the brain.
Neurosphere diameter is a metric for proliferation of neural progenitor cells (which are unique and distinct from NSCs) (Figure 15B). Both the B4 and Gold cultivars increased the proliferation of neural progenitors. Together, these data demonstrate the ability of plant-derived EV to deliver therapeutic drugs to the brain via intranasal delivery.
Given the ability to both bioengineer the hemp plant for enriched production of certain cannabinoids (or harvest EVs from different hemp cultivars) provides a cannabinoid delivery system that can be used to treat non-cancer conditions such as concussion, injury and degenerative diseases. Commercial relevance for this technology is high given several ongoing clinical trials evaluating cannabinoids in brain cancers, neurodegenerative disease, pain, etc.
Although the present invention has been described in considerable detail with reference to certain preferred versions thereof, other versions are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of the preferred versions contained herein.
The reader's attention is directed to all papers and documents which are filed concurrently with this specification and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
All the features disclosed in this specification (including any accompanying claims, abstract, and drawings) may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.
Any element in a claim that does not explicitly state "means for" performing a specified function, or "step for" performing a specific function, is not to be interpreted as a "means" or "step" clause as specified in 35 U.S.0 112, sixth paragraph. In particular, the use of "step of"
in the claims herein is not intended to invoke the provisions of 35 U.S.0 112, sixth paragraph.
(v) any artificial process for separating a molecule or structure of interest from at least one other component with which it is normally associated (e.g., purifying). or (vi) any combination of (i), (ii), (iii), (iv) or (v).
Similarly, as used herein, the term "isolated" generally refers to the state of the molecule or structure of interest after the starting material has been subjected to a method for isolating the molecule of interest. That is to say, isolating a molecule of interest or structure of interest from a starting material will produce an isolated molecule. For example, the methods of the invention are used to produce preparations of isolated extracellular vesicles.
The term "neurodegenerative disease" as used herein refers to a condition that involve degeneration of neurons in the CNS system. Examples of neurodegenerative diseases include, but are not limited to, one or more of Alzheimer's disease, Parkinson' s disease, Huntington' s disease, motor neuron disease, spinocerebellar ataxia, and spinal muscular atrophy.
The term "CNS injuries" as used herein refers to injury or trauma to the CNS
of a subject.
Examples of CNS injuries include, but are not limited to one or more of stroke, traumatic brain injury, concussion, and spinal cord injury.
The term "inflammatory condition" as used herein refers to refers to any inflammatory disease or disorder known in the art whether of a chronic or acute nature.
Examples of inflammatory conditions treatable by the compositions described herein include auto-immune diseases (e.g. multiple sclerosis, encephalitis and the like.
The term "payload" as used with respect to PEVs refers to constituents contained by individual extracellular vesicles. In various embodiments, the extracellular vesicle membrane comprises an interior surface and an exterior surface and encloses an internal space. In certain embodiments, the payload is enclosed within the internal space. In other embodiments, the payload is displayed on the external surface of the extracellular vesicle. In other embodiments, the payload spans the membrane of the extracellular vesicle. In various embodiments, the payload comprises nucleic acids, proteins, carbohydrates, lipids, small molecules, and/or combinations thereof. The PEVs may contain both exogenous and/or endogenous payloads.
Further, endogenous payloads can be enriched above that which is found in nature. Payloads for loading into PEVs (i.e. exogenous payloads) may include a select therapeutic agent that are artificially chemical synthesized and/or isolated from other sources, including other plant or fungal material.
The term -PEV composition" refers to a PEVs combined with a carrier.
As used herein, the term "plant" refers to whole plants (e.g., whole seedlings or whole adult plants), plant organs, plant parts, plant tissues, seeds, plant cells, seeds, and progeny of the same.
As used herein, the term -plant extracellular vesicle" or -PEV" refers to a lipid structure (e.g., a lipid bilayer, unilamellar, multilamellar structure; e.g., a vesicular lipid structure), that is about 5-2000 nm (e.g., at least 5-1000 nm, at least 5-500 nm. at least 400-500 nm, at least 25-250 nm, at least 50-150 nm, or at least 70-120 nm) in diameter that is derived from (e.g., enriched, isolated or purified from) a plant source or segment, portion, or extract thereof, including lipid or non-lipid components (e.g., peptides, nucleic acids, or small molecules) associated therewith and that has been enriched, isolated or purified from a plant, a plant part, or a plant cell or from a culture medium in which a plant, plant part, or plant cell has been cultured (e.g., a culture medium of a plant cell culture or a hydroponic culture, e.g., secreted PEVs), the enrichment or isolation removing one or more contaminants or undesired components originating from the source plant, plant part, or plant cell or from the culture medium. In some examples, the isolation comprises removing an intact plant or plant part from the culture medium (e.g., a culture medium of a hydroponic system), e.g., removing the plant or plant part without disrupting (e.g., physically damaging) the plant or plant part. PEVs may be highly purified preparations of naturally occurring EVs. Preferably, at least 1 % of contaminants or undesired components from the source plant are removed (e.g., at least 2%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 45%, 50%, 55%, 60%, 70%, 80%, 90%, 95%, 96%, 98%, 99%, or 100%) of one or more contaminants or undesired components from the source plant, e.g., plant cell wall components; pectin; plant organelles (e.g., mitochondria; plastids such as chloroplasts, leucoplasts or amyloplasts; and nuclei); plant chromatin (e.g., a plant chromosome); or plant molecular aggregates (e.g., protein aggregates, nucleic acids, proteins, protein-nucleic acid aggregates, lipoprotein aggregates, lipido-proteic structures, or sugars). Preferably, a PEV is at least 30% pure (e.g., at least 40%
pure, at least 50% pure, at least 60% pure. at least 70% pure, at least 80%
pure, at least 90%
pure, at least 99% pure, or 100% pure) relative to the one or more contaminants or undesired components from the source plant as measured by weight (w/w), spectral imaging (%
transmittance), or conductivity (S/m). PEVs may encompass exosomes or microvesicles.
Generally, PEVs comprise a payload that can be delivered to a cell upon association of the PEV
with the cell. Exemplified herein are PEVs obtained from plant material of a Cannabis spp plant. As used herein, csPEV refers to a PEV from a Cannabis spp.
CPEVs may optionally include additional agents, such as heterologous functional agents, e.g., therapeutic agents, polynucleotides, polypeptides, or small molecules.
The CPEVs can carry or associate with additional agents (e.g., heterologous functional agents) in a variety of ways to enable delivery of the agent to a target plant, e.g., by encapsulation of the agent, incorporation of the agent in the lipid bilayer structure, or association of the agent (e.g., by conjugation) with the surface of the lipid bilayer structure. Exogenous functional agents can be incorporated into the CPEVs either in vivo (e.g., in planta) or in vitro (e.g., in tissue culture, in cell culture, or synthetically incorporated).
As used herein, the terms "purified" or "partially purified" refers to molecules or structures of interest that are removed from either (1) their natural environment, or from (2) a starting material (i.e., they are isolated), and where (a) at least one impurity from the starting material has been removed, or (b) at least one component with which the molecule is naturally associated has been removed. A "purified" or "partially purified" molecule may still contain additional components that may render future use or study of the molecule sub-optimal, difficult or impossible.
As used herein, the term -purifying" or "to purify" a molecule or structure of interest refers to a process for removing at least one impurity or contaminant from a starting material.
For example, purifying a molecule of interest from a starting material refers to a process for removing at least one impurity from the starting material to produce a relatively more pure form of the molecule of interest.
In a certain embodiment, a CPEV composition of this disclosure can be administered to a subject who has symptoms of or is diagnosed with a cancer. A composition of this invention can be administered prophylactically, i.e., before development of any symptom or manifestation of the disease, disorder or condition. Typically, in this case the subject will be at risk of developing the condition. Treating also may comprise treating a subject exhibiting symptoms of a certain disease, disorder or condition.
As used herein, the term "subject" refers to an animal being treated with CPEVs as taught herein. The term includes any animal, preferably a mammal, including, but not limited to, farm animals, zoo animals, companion animals, service animals, laboratory or experimental model animals, sport animals. More specific examples include simians, avians, felines, canines, equines, rodents, bovines, porcines, ovines, and caprines. The term specifically includes humans and human patients. In a specific embodiment, subjects pertain to human cancer patients or humans in need of treatment for cancer, including glioblastoma. A suitable subject for the invention can be any animal, preferably a human, that is suspected of having, has been diagnosed as having, or is at risk of developing a disease that can be ameliorated, treated or prevented by administration of one or more CPEVs. Therefore, a "subject in need" refers to a subject as defined herein that is suspected of having, has been diagnosed as having, or is at risk of developing a disease that can be ameliorated, treated or prevented by administration of one or more CPEVs and compositions including same.
As used herein, the term "substantially purified" refers to molecules or structures of interest that are removed from their natural environment or from a starting material (i.e., they are isolated) and where they are largely free from other components with which they are naturally associated or substantially free of other components that may render future use or study sub-optimal, difficult or impossible.
A "therapeutically effective amount" refers to an amount which, when administered in a proper dosing regimen, is sufficient to reduce or ameliorate the severity, duration, or progression of the disorder being treated (e.g., cancer), prevent the advancement of the disorder being treated (e.g., cancer), cause the regression of the disorder being treated (e.g., cancer), or enhance or improve the prophylactic or therapeutic effects(s) of another therapy. The full therapeutic effect does not necessarily occur by administration of one dose and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations per day for successive days.
The terms "treat", "treating" or "treatment of' as used herein refers to providing any type of medical management to a subject. Treating includes, but is not limited to, administering a composition to a subject using any known method for purposes such as curing, reversing, alleviating, reducing the severity of, inhibiting the progression of, or reducing the likelihood of a disease, disorder, or condition or one or more symptoms or manifestations of a disease, disorder or condition.
Plant Extracellular Vesicles A plant extracellular vesicle including exosomes, are nanoscale membrane-enclosed particles implicated in intercellular communication to facilitate transport of proteins and genetic material. Plant extracellular vesicles can have, but not be limited to, a diameter of greater than about about 5-2000 nm (e.g., at least 5-1000 nm, at least 5-500 nm, at least 400-500 nm, at least 25-250 nm, at least 50-150 nm, or at least 70-120 nm).
As used herein, plant extracellular vesicles can also include any shed membrane bound particle that is derived from either the plasma membrane or an internal membrane. Plant extracellular vesicles can also include cell-derived structures bounded by a lipid bilayer membrane arising from both herniated evagination (blebbing) separation and sealing of portions of the plasma membrane or from the export of any intracellular membrane-bounded vesicular structure containing various membrane-associated proteins. Plant extracellular vesicles can also include membrane fragments.
Plant extracellular vesicles can be directly assayed from the biological samples, such that the level of plant extracellular vesicles is determined or the one or more biomarkers of the plant extracellular vesicles are determined without prior isolation, purification, or concentration of the plant extracellular vesicles. Alternatively, plant extracellular vesicles may be isolated, purified, or concentrated from a sample prior to analysis.
Analysis of a plant extracellular vesicle can include quantitating the amount one or more plant extracellular vesicle populations of a biological sample. For example, a heterogeneous population of plant extracellular vesicles can be quantitated, or a homogeneous population of plant extracellular vesicles, such as a population of plant extracellular vesicles with a particular biomarker profile, a particular bio-signature, or derived from a particular cell type (cell-of-origin specific plant extracellular vesicles) can be isolated from a heterogeneous population of plant extracellular vesicles and quantitated. Analysis of a plant extracellular vesicle can also include detecting, quantitatively or qualitatively, a particular biomarker profile or a bio-signature, of a plant extracellular vesicle, as described below.
A plant extracellular vesicle can be stored and archived, such as in a bio-fluid bank and retrieved for analysis as necessary. A plant extracellular vesicle may also be isolated from a biological sample that has been previously harvested and stored from a living or deceased subject. In addition, a plant extracellular vesicle may be isolated from a biological sample or isolated from an archived or stored sample. Alternatively, a plant extracellular vesicle may he isolated from a biological sample and analyzed without storing or archiving of the sample.
Furthermore, a third party may obtain or store the biological sample, or obtain or store the plant extracellular vesicles for analysis.
An enriched population of plant extracellular vesicles can be obtained from a biological sample. For example, plant extracellular vesicles may be concentrated or isolated from a biological sample using size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof. These methods can be used to separate plant extracellular vesicles from contaminants.
Size exclusion chromatography, such as gel permeation columns, centrifugation or density gradient centrifugation, and filtration methods can be used. For example, plant extracellular vesicles can be isolated by differential centrifugation, anion exchange and/or gel permeation chromatography (for example, as described in U.S. Pat. Nos.
6,899,863 and 6,812,023), sucrose density gradients, organelle electrophoresis (for example, as described in U.S. Pat. No. 7,198,923), magnetic activated cell sorting (MACS), or with a nanomembrane ultrafiltration concentrator. Various combinations of isolation or concentration methods can be used.
Isolation or enrichment of plant extracellular vesicles from biological samples can also be enhanced by use of sonication (for example, by applying ultrasound), or the use of detergents, other membrane- active agents, or any combination thereof.
Administration In some embodiments, the composition embodiments comprising CPEVs described herein will be administered intranasally to a mammalian subject in need thereof using a level of pharmaceutical composition that is sufficient to provide the desired physiological effect. The mammalian subject may be a domestic animal or pet but preferably is a human subject. The level of pharmaceutical composition needed to give the desired physiological result is readily determined by one of ordinary skill in the art. Other parameters that may be taken into account in determining dosage for the pharmaceutical composition embodiments described herein may include disease state of the subject or age of the subject. The composition will typically include an excipient for intranasal delivery.
The compositions may take the form of suspensions, solutions or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. In some embodiments, the composition embodiments described herein may be administered orally or intravenously (e.g. via parenteral nutritional therapy) to a subject via an emulsion. The emulsion may include, in some embodiments, an aqueous continuous phase and a dispersed phase. The boundary between the phases called the "interface". The present emulsions are adapted for application to a mucosal surface of a vertebrate animal, preferably a mammal, including humans. These compositions improve the permeability and bioavailability of active compounds after application to a mucous surface. Mucosal surfaces of interest include the intestinal mucosa. Use of bioadhesive polymers in pharmaceutical emulsions affords enhanced delivery of drugs in bioadhesive polymer-coated suspensions, in some examples.
Bioadhesive pharmaceutical emulsions may be used to deliver the described herein to: a) prolong the residence time in situ, thereby decreasing the number of drug administrations required per day;
and b) may be localized in the specified region to improve and enhance targeting and bioavailability of delivered drugs.
The ability to retain and localize a CPEV delivery emulsion in a selected region leads to improved bioavailability, especially for drugs exhibiting a narrow window of adsorption due to rapid metabolic turnover or quick excretion. Intimate contact with the target absorption membrane improves both the extent and rate of drug absorption.
Bioadhesion is the characteristic of certain natural and synthetic polymers of binding to various biological tissues. Of particular interest are polymers which bind to the mucous lining that covers the surface of many tissues which communicate directly or indirectly with the external environment, such as the nasal mucosa, for example. Mucus binding polymers may be referred to as mucoadhesive. Several bioadhesive, and specifically mucoadhesive, polymers are known. The chemical properties of the main mucoadhesive polymers are summarized as follows:
a. strong H-bonding groups (--OH, --COOH) in relatively high concentration;
b. strong anionic charges;
c. sufficient flexibility of polymer backbone to penetrate the mucus network or tissue crevices;
d. surface tension characteristics suitable for wetting mucus and mucosal tissue surfaces;
and e. high molecular weight.
Bioadhesive polymers may be used in the pharmaceutical composition embodiments described herein, examples of bioadhesive polymers currently used in pharmaceutical preparations include: carboxymethylcellulose (CMC), hydroxypropylmethylcellulose (HPMC), polyacrylic and polymethacrylic acid and their derivatives, pectin, alginic acid, chitosan, polyvinylpyrrolidone, hyaluronic acid, and polyvinyl alcohol. The most frequently used polymer is Carbopol (Carbomer), which is a high molecular weight polyacrylic acid polymer. It is used in many formulations for bioadhesive drug delivery systems, as a suspending agent, as a tablet coating, and in ocular suspensions.
Pharmaceutical composition embodiments described herein may include the composition comprising PEVs, CPEVs or csPEVs incorporated into inert lipid carriers such as oils, surfactant dispersions, emulsions, liposomes etc. Self-emulsifying formulations are ideally isotropic mixtures of oils, surfactants and co-solvents that emulsify to form fine oil in water emulsions when introduced in aqueous media. Fine oil droplets would pass rapidly from stomach and promote wide distribution of drug throughout the GI tract, thereby overcome the slow dissolution step typically observed with solid dosage forms. These embodiments may provide control release self-emulsifying pellets, microspheres, tablets, capsules etc. that increase the use of "self-emulsification."
Intranasal delivery is the typical mode of administration to deliver the PEVs, CPEVs or csPEVs to a subject in need. However, in alternative embodiments, other methods of administration are contemplated. Accordingly, suitable methods for administering a PEV, CPEV
or csPEV containing composition in accordance with the methods of the presently-disclosed subject matter include, but arc not limited to, oral administration, systemic administration, parenteral administration (including intravascular, intramuscular, and/or intraarterial administration), oral delivery, buccal delivery, rectal delivery, subcutaneous administration, intraperitoneal administration, inhalation, dermally (e.g., topical application), intratracheal installation, surgical implantation, transdermal delivery, local injection, and hyper-velocity injection/bombardment. Where applicable, continuous infusion can enhance drug accumulation at a target site (see, e.g., U.S. Pat. No. 6,180,082). In some embodiments of the therapeutic methods described herein, the therapeutic compositions are administered orally, intravenously, intranasally, or intraperitoneally to thereby treat a disease or disorder.
Regardless of the route of administration, the compositions of the presently-disclosed subject matter typically not only include an effective amount of a PEVs, but are typically administered in amount effective to achieve the desired response. As such, the term "effective amount" is used herein to refer to an amount of the therapeutic composition (e.g., a PEVs and a pharmaceutically vehicle, carrier, or excipient) sufficient to produce a measurable biological response (e.g., reduction in cancer cells). Actual dosage levels of active ingredients in a therapeutic composition of the present invention can be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular subject and/or application. Of course, the effective amount in any particular case will depend upon a variety of factors including the activity of the therapeutic composition, formulation, the route of administration, combination with other drugs or treatments, severity of the condition being treated, and the physical condition and prior medical history of the subject being treated. Preferably, a minimal dose is administered, and the dose is escalated in the absence of dose-limiting toxicity to a minimally effective amount.
Deteimination and adjustment of a therapeutically effective dose, as well as evaluation of when and how to make such adjustments, are known to those of ordinary skill in the art. Background information on formulations of extracellular vesicles and loading EVs with exogenous payloads is taught in U.S.
Patent No. 10,723,782, and Tran et al. "Exosomes as Nanocarriers for Immunotherapy of Cancer and Inflammatory Diseases. (2015) Clin Immunol. PMID: 25842185.
Kits In view of the new findings described herein that cannabinoids packaged in plant extracellular vesicles can improve delivery of cannabinoids to tissues or cells (tumor or normal cells), kits are provided that include a container for housing the PEVs and an applicator for delivery of the PEVs. In a specific example, the applicator includes a tapered spout for insertion into a nostril of a subject that attaches to the container. The CPEV
compositions described herein can be administered to the nasal cavity in any suitable form, for example in the form of drops or sprays.
Methods suitable for administering a CPEV or csPEV composition to the nasal cavity will be well known by the person of ordinary skill in the art. Any suitable method may be used.
The preferred method of administration is the use of a spray device. Spray devices can be single (unit) dose or multiple dose systems, for example comprising a bottle, pump and actuator, and are available from various commercial sources including Pfeiffer, Valois, Bespak and Becton-Dickinson. Electrostatic spray devices, such as described in U.S. Pat. No.
5,655,517, are also suitable for the intranasal administration of the compositions of the present invention.
For a spray device, the typical volume of liquid that is dispensed in a single spray actuation is in the range of from 0.01 to 0.15 ml. A typical dosing regimen for a nasal spray product would be in the range of one spray into a single nostril to two sprays into each nostril.
The present invention also provides a spray device loaded with a composition as defined above.
EXAMPLES
To this end, we have discovered and isolated naturally occurring hemp extracellular vesicles (EVs) that are enriched with a payload of cannabinoids in acidic forms. Floral parts of fresh hemp plant were juiced. Hemp juice was first centrifuged at different speeds (from 2000-35000 xg) and filtered through different size paper filters to remove debris and particles larger than 0.221aM and then was transferred to ultracentrifuge tubes and centrifuged at 150,000 xg for 1 hour in a Beckman Coulter OptimaTM XE ultracentrifuge with a Type 45 Ti rotor. The EV
pellet was resuspended in sterile PBS and stored in -80 C freezer.
Nanotracking analysis (NTA, Nanosight NS300 instrument) has shown that hemp EVs have a median diameter of 112.6 nm (Figure 1A). Transmission electron microscopy (TEM, Tecnai G2 F20-TWIN) evaluation has validated the size and morphology of hemp EVs with a lipid bilayer structure typical of the EVs (Figure 1B). Major cannabinoid content of hemp EVs (CBD, CBD-A, THC, THC-A, CBG, CBG-A) was quantified using Liquid chromatography tandem mass spectrometry (LC-MS/MS).
Analytes were extracted from the EVs using solid phase extraction (C18 cartridge) method. EV
samples were spiked with deuterated internal standards prior to the extraction to check recovery and correction of extraction efficiency. Our results have shown that CBD-A, CBG-A, THC-A, CBD, and THC represent 69.1 2.1%, 19.1 1.6%, 6.5 0.54%, 4.75 0.26%, and 0.5 0.3%
of the total cannabinoids in hemp EVs (Figure 1C) without any detectable level of CBG.
To assay the uptake of EVs by cells, we labelled hemp EVs with SYTOTM
RNASelectTM green fluorescent cell stain as per manufacturer's instructions and removed excess unincorporated dye from the labelled EVs with exosome spin columns (MW
3000).
Human glioblastoma tumor cells were plated in laminin coated coverslip in growth medium overnight and then the labeled EVs were added to each well and EVs uptake by the cells was assessed 3 hours later. Our results show that EVs can be taken up by GBM cells in vitro presenting a characteristic dotted staining pattern in contrast to a uniform cytoplasmic staining pattern of cells exposed to the free dye (Figure 2). In vitro anti-glioma effects of the hemp EVs were studied both in human and murine GBM cell lines. First, the mean CBD-A
concentration per EV and then the number of EVs equal to a certain CBD-A concentration was calculated based on the LC-MS/MS results. Tumor cells were plated in 96 wells in neurosphere growth medium supplemented with hemp EVs corresponding to different CBD-A
concentrations. After 7 days, the mean fluorescent intensity (as an index of cell proliferation) was measured and nonnalized based on that of the control condition using Alamar Blue assay.
Hemp EVs have shown significant anti-glioma effect starting at a number that is equivalent to or more than liaM
of CBD-A (Figure 3A,B). Overnight incubation of human GBM tumor cells with a non-killing dose of hemp EVs effectively reduces GBM cell migration in a transwell migration assay (Figure 3C). In order to test the intranasal delivery of hemp EVs, we used a C57/B16 mouse with an established KR-158 tumor in the left hemisphere and delivered 12ittl of SYTOTM
RNASelectTM
green fluorescent labelled hemp EVs in both nostrils ( 2 Onostril every 5 minutes).
The animal were sacrificed 24 hours later and brain tissue was fixed, cryosectioned and stained for anti-nestin antibody and counterstained with DAPI to distinguish the tumor vs non-tumor areas of the brain, labelled hemp EVs are scattered throughout the brain hemispheres (Figure 4).
To assay antitumor effect of hemp EVs, a cohort of animals were implanted with tumor. Three days after implantation, the animals were randomly placed in two groups receiving either PBS (vehicle of hemp EVs, control group) or hemp EVs every day intranasally for 35 days (twice daily with 6 hour interval between the two intranasal deliveries).
Immunofluorescence analysis of brain tissue for Iba-1 in control and hemp EV treated group showed a distinct difference in microglial cell morphology and density between the two groups (Figure 5 A,B).
Animal survival analysis using Log-rank test revealed that hemp EV therapy significantly increased animal survival and slowed down tumor growth (Figure 6). LC-MS/MS
analysis of cannabinoid content of the brain (Figure 7) and KR-158 tumor tissue (Figure 8) showed that intranasal hemp EV delivery leads to a substantial amount of CBD-A and CBG-A
in these tissues. This discovery is exciting because delivering hemp EVs with its natural cannabinoid payload directly into the brain via noninvasive intranasal approach will improve killing of malignant brain tumor cells, thereby increasing treatment response, improving patient survival and potentially achieving a cure. Intranasal delivery of cannabinoids in natural nanovesicle form holds a great promise circumventing the systemic effects of cannabinoid oral delivery and bypassing first pass metabolism in liver. Additionally, intranasal delivery method of cannabinoids represents a promising, safe and gentle alternative to the invasive, inconvenient and costly delivery methods such as intratumoral approach delivery approach for brain tumors. Hemp EVs have an endogenous payload of cannabinoids and the technology can rapidly move into clinical testing.
Cannabidiolic acid (CBDa) was dissolved in PBS (64 ng/lOul) or hemp EVs, isolated, and diluted to have the same CBDa concentration as purified CBDa. C57/B6 mice received a single dose (10 pl purified CBDa or 10p1 of hemp EVs) intranasally. One hour after treatment animals were killed, brains removed and CBDa content analyzed with Linear Ion Trap Quadrupole LC-MS/MS (AB SCIEX Instruments). CBDa levels in the brain were 5-fold higher when delivered with hemp EVs (Figure 9).
C57/B6 mice were gavaged with hemp derived EV containing approximately 6.411g of CBDa and 0.140pg THCa. One, 3,6 and 12 hours post gavage animals were killed, brains removed and CBDa and THCa content analyzed with Linear Ton Trap Quadrupole LC-MS/MS
[AB SCIEX Instruments]. Peak levels of CBDa and THCa were seen at 1 hour post gavage, with concentrations being 2.5 ng/mg and 0.06 ng/mg of brain tissue, respectively (Figure 10A). This can be compared to Anderson et al., 2019* who delivered by IP injection approximately 300iag of CBDa or THCa to C57/B6 mice, either dissolved in vegetable oil or in ethanol Tween-80 solution and analyzed plasma and brain levels of each compound (Figure 10B).
While THCa levels were below detection in the brain, CBDa demonstrated a Cmax at 30 mins with concentrations of 2.0 ng/mg and 13.2 ng/mg in vegetable oil or Tween-80, respectively.
Comparison between Anderson et al., 2019 and plant EV delivery (Figure 10C).
Percentage of CBDa or THCa in brain (ng/mg of tissue/dosage) for each method demonstrates the plant EV
have a 7.5 - 43 fold increase in CBDa brain penetration over Tween-80 or vegetable oil vehicles, respectively. THCa penetration with plant EVs were similar to CBDa.
TBI was induced using a unilateral fluid percussion injury (FPI) model and the animals were treated with either 10 1.11 of PBS or hemp EVs one hour after injury, twice daily for 7days.
Animals were bled at 24 hrs, 72 hrs and 7 days post-TBI and sacrificed on day 7. Western blot analysis of GFAP and Spectrin protein levels in the injured cortex of the control and plant EV
treated TBI animals (Figure 11A-B). A significant reduction in GFAP and Spectrin protein levels are seen in the plant EV treated TBI animals. Inflammatory cytokine analysis using (V-PLEX proinflammatory panel (Mesoscale Diagnostics)) at 24 hours, 72 hours and 7 days post injury reveal that plant EVs result in a significant increase in anti-inflammatory cytokines at 72 hours for IL-4 (Figure 11C) & IL-10 (Figure 11D).
TBI was induced using a unilateral fluid percussion injury (FPI) model and the animals were treated with either 10 1.11 of PBS or hemp EVs one hour after injury, twice daily for 7 days.
Animals were sacrificed on day 7 for brain histological analysis. Control brains IBA-11 (rabbit anti-IBA-1, Encor biotechnology) is upregulated in microglia signifying their activation (Figure 12A). EV treated animals demonstrate a qualitative reduction in IBA-1 microglia expression supporting the notion that plant EVs are able to attenuate inflammation and microglia activation following TBI (Figure 12B).
Plant EV increased survival of KR-1861uc glioma bearing mice. EV treatment increased median survival (log-rank test, from 31 to 42 days) (Figure 13).
After performing a dose-response analysis to determine the effective antiproliferative concentration (LD50) of the hemp EVs, glioma (mouse KR-158 and human LO) cells were plated in the neurosphere assay culture and treated with three doses of hemp EVs (number of EVs corresponding to their CBDa concentration) that were less than LD50. After 7 days in culture the number and size of neurospheres were determined in each condition. With increasing concentration of the hemp EVs, both the neurosphere forming frequency and neurosphere size decrease which together shows antiproliferative effect of the hemp EVs on glioma cells (Figure 14A). Using a mathematical model, serial passaging of the glioma cells in neurophere culture supplemented with an effective antiproliferative dose of the hemp EVs (1 ilM) have shown that hemp EVs significantly reduce symmetric cell division in glioma stem cells resulting in a significant decrease in glioma tumor cells expansion over time (Figure 14B).
Different hemp cultivars (B4 CBDa and Gold CBGa enriched) were used to isolated EVs, which were subsequently concentrated and delivered intranasally twice a day for 7 days. Animals were killed, subventricular zone micro-dissected, tissue dissociated and placed in the Neurosphere Assay. Seven to 10 days later the number of spheres and their diameter where quantitated. Sphere-fat __________________________________________________________ ming frequency is a reflection of the number of NSCs in vivo and was increased by the Gold EVs (Figure 15A). B4 cultivar, which is enriched in CBDa did not increase the number of NSCs while both Gold EVs, containing decarboxylated CBG
and the acidic form of CB G (CBGa), significantly increased the number of NSCs in the brain.
Neurosphere diameter is a metric for proliferation of neural progenitor cells (which are unique and distinct from NSCs) (Figure 15B). Both the B4 and Gold cultivars increased the proliferation of neural progenitors. Together, these data demonstrate the ability of plant-derived EV to deliver therapeutic drugs to the brain via intranasal delivery.
Given the ability to both bioengineer the hemp plant for enriched production of certain cannabinoids (or harvest EVs from different hemp cultivars) provides a cannabinoid delivery system that can be used to treat non-cancer conditions such as concussion, injury and degenerative diseases. Commercial relevance for this technology is high given several ongoing clinical trials evaluating cannabinoids in brain cancers, neurodegenerative disease, pain, etc.
Although the present invention has been described in considerable detail with reference to certain preferred versions thereof, other versions are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of the preferred versions contained herein.
The reader's attention is directed to all papers and documents which are filed concurrently with this specification and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
All the features disclosed in this specification (including any accompanying claims, abstract, and drawings) may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.
Any element in a claim that does not explicitly state "means for" performing a specified function, or "step for" performing a specific function, is not to be interpreted as a "means" or "step" clause as specified in 35 U.S.0 112, sixth paragraph. In particular, the use of "step of"
in the claims herein is not intended to invoke the provisions of 35 U.S.0 112, sixth paragraph.
Claims (29)
- What is claimed is:
I. A method for treating a brain cancer in a subject in need, comprising administering to the subject in need a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs). - 2. The method of claim 1, wherein the composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.
- 3. The method of claims 1 or 2, wherein the CPEVs are administered intranasally.
- 4. The method of any of claims 1-3, wherein the administering comprises administering the CPEVs intranasally using a nasal delivery device selected from the group consisting of an intranasal inhaler, an intranasal spray device, an atomizer, a nebulizer, a metered dose inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit dose container, a pump, a dropper, a nasal spray bottle, a squeeze bottle and a bi-directional device.
- 5. The method of any of claims 1-4, further comprising co-administering an adjunct cancer therapy protocol.
- 6. Thc method of claim 5, wherein the adjunct cancer therapy protocol comprising trcating the mammal with radiation before, during, or after the administration of the CPEVs
- 7. The method of claim 5, wherein the adjunct cancer therapy protocol comprising an additional chemotherapeutic agent.
- 8. A composition comprising CPEVs and a pharmaceutically acceptable carrier.
- 9. The composition of claim 8, wherein the pharmaceutically acceptable carrier comprises an excipient for intranasal delivery.
- 10. A device comprising a container, wherein a CPEV composition is disposed within said container, and a spout associated with the container that is configured for insertion into a nostril of a subject in need.
- 11. A method for treating a neurodegenerative disease in a subject in need, comprising administering to the subject in need a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs).
- 12. The method of claim 11, wherein the composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.
- 13. The method of claim 11, wherein the neurodegenerative disease comprises stroke, Alzheimer's disease, ALS, MS, Parkinson's disease, traumatic brain injury, or aging.
- 14. A method for treating a CNS injury in a subject in need, comprising administering to the subject in need a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs).
- 15. The method of claim 14, wherein the composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.
- 16. A method for treating an inflammatory condition in a subject in need, comprising administering to the subject in need a therapeutically effective amount of cannabinoid containing plant extracellular vCsicles (CPEV s).
- 17. The method of claim 16, wherein the composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.
- 18. A method for augmenting function of a CNS in a subject. comprising administering to the subject in need a therapeutically effective amount of cannabinoid containing plant extracellular vesicles (CPEVs).
- 19. The method of claim 18, wherein the composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.
- 20. A method of making csPEVs comprising obtaining PEVs from a Cannabis spp.; and loading the PEVs with an exogenous payload.
- 21. A composition comprising csPEVs loaded with an exogenous payload.
- 22. A method of delivering a payload to a subject comprising administering an effective amount of the composition of claim 21 to the subject.
- 23. The method of claim 22, wherein administering comprises intranasal delivery or parenteral delivery of the composition.
- 24. The method of claim 23, wherein the composition is administered by inhalation, intranasally, orally, intravenously, subcutaneously or intramuscularly.
- 25. A device comprising a container, wherein an amount of the composition of claim 21 is disposed within said container.
- 26. The device of claim 25, further comprising a spout associated with the container that is configured for insertion into a nostril of a subject in need.
- 27. The method of any of claims 1-7, wherein the CPEVs contain CBD-A, CBG-A, THC-A, CBD, and THC at 69.1 2.1%, 19.1 1.6%, 6.5 0.54%, 4.75 0.26%, and 0.5 0.3%, of total cannabinoids, respectively.
- 28. A composition of claim 8, wherein the CPEVs contain CBD-A, CBG-A, THC-A, CBD, and THC at 69.1 2.1%, 19.1 1.6%, 6.5 0.54%, 4.75 0.26%, and 0.5 0.3%, of total cannabinoids, respectively.
- 29. The method of any of claims 11-19, wherein the CPEVs contain CBD-A, CBG-A, THC-A, CBD, and THC at 69.1 2.1%, 19.1 1.6%, 6.5 0.54%, 4.75 0.26%, and 0.5 0.3%, of total cannabinoids, respectively.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063084193P | 2020-09-28 | 2020-09-28 | |
US63/084,193 | 2020-09-28 | ||
PCT/US2021/052284 WO2022067223A2 (en) | 2020-09-28 | 2021-09-28 | Cannabis plant derived extracellular vesicles and therapeutic methods using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3193856A1 true CA3193856A1 (en) | 2022-03-31 |
Family
ID=80846948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3193856A Pending CA3193856A1 (en) | 2020-09-28 | 2021-09-28 | Cannabis plant derived extracellular vesicles and therapeutic methods using the same |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240024227A1 (en) |
EP (1) | EP4217073A2 (en) |
JP (1) | JP2023543260A (en) |
KR (1) | KR20230079158A (en) |
CN (1) | CN116600795A (en) |
AU (1) | AU2021350200A1 (en) |
CA (1) | CA3193856A1 (en) |
GB (1) | GB2615671A (en) |
WO (1) | WO2022067223A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024155941A1 (en) * | 2023-01-19 | 2024-07-25 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Plant-based extracellular-like vesicles for biotherapeutic applications |
WO2024155158A1 (en) * | 2023-01-19 | 2024-07-25 | 넥스탭 주식회사 | Composition for prevention or treatment of cancer, comprising extracellular vesicles derived from edible crops |
CN117298153B (en) * | 2023-08-30 | 2024-03-08 | 济宁市第一人民医院 | Application of extracellular vesicles derived from brain endothelial cells in neuroinflammation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9084771B2 (en) * | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
CA2956919C (en) * | 2014-07-21 | 2022-07-19 | Glia, Llc | Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids |
JP2020521810A (en) * | 2017-05-26 | 2020-07-27 | アルツム ファーマシューティカルス インコーポレーテッド | Biphasix and cannabinoid delivery |
KR20210013580A (en) * | 2018-05-15 | 2021-02-04 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | Pest control composition and use thereof |
-
2021
- 2021-09-28 CN CN202180077868.XA patent/CN116600795A/en active Pending
- 2021-09-28 WO PCT/US2021/052284 patent/WO2022067223A2/en active Application Filing
- 2021-09-28 JP JP2023519177A patent/JP2023543260A/en active Pending
- 2021-09-28 AU AU2021350200A patent/AU2021350200A1/en active Pending
- 2021-09-28 GB GB2306011.4A patent/GB2615671A/en active Pending
- 2021-09-28 CA CA3193856A patent/CA3193856A1/en active Pending
- 2021-09-28 KR KR1020237014489A patent/KR20230079158A/en unknown
- 2021-09-28 US US18/028,937 patent/US20240024227A1/en active Pending
- 2021-09-28 EP EP21873622.1A patent/EP4217073A2/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4217073A2 (en) | 2023-08-02 |
GB202306011D0 (en) | 2023-06-07 |
CN116600795A (en) | 2023-08-15 |
JP2023543260A (en) | 2023-10-13 |
KR20230079158A (en) | 2023-06-05 |
US20240024227A1 (en) | 2024-01-25 |
GB2615671A (en) | 2023-08-16 |
WO2022067223A2 (en) | 2022-03-31 |
AU2021350200A1 (en) | 2023-06-08 |
WO2022067223A3 (en) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240024227A1 (en) | Cannabis plant derived extracellular vesicles and therapeutic methods using the same | |
US10799457B2 (en) | Exosomal compositions and methods for the treatment of disease | |
US20230149316A1 (en) | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease | |
Mancini et al. | Functionalized liposomes and phytosomes loading Annona muricata L. aqueous extract: Potential nanoshuttles for brain-delivery of phenolic compounds | |
US11793883B2 (en) | Water-based cannabinoid and opioid compositions | |
Wen et al. | Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration | |
Priprem et al. | Anxiety and cognitive effects of quercetin liposomes in rats | |
US9717733B2 (en) | Edible plant-derived microvesicle compositions including conjugated therapeutic agents and methods for using the same | |
WO2015142501A1 (en) | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids | |
US10117883B2 (en) | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids | |
EP3501500A1 (en) | All-trans retinoic acid liposome preparation, and preparation and application thereof | |
Kuo et al. | Glutathione-and apolipoprotein E-grafted liposomes to regulate mitogen-activated protein kinases and rescue neurons in Alzheimer's disease | |
US11975036B2 (en) | Methods of treating ovarian cancer with hemp extract | |
EP4415739A1 (en) | Compositions and methods for treating neurological disorders with combination products | |
Mahdinloo et al. | Synthesis and preparation of vitamin A coupled butein-loaded solid lipid nanoparticles for liver fibrosis therapy in rats | |
CA3231509A1 (en) | Compositions and methods for treating neurological disorders | |
BR112021015387A2 (en) | CANABINOID RECEPTOR AGONISTS AND ANXIOLYTIC THERAPEUTIC PRODUCT BASED ON SERINE HYDROLASE ENZYMATIC INHIBITOR | |
US20230131989A1 (en) | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders | |
US20230067205A1 (en) | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders | |
WO2024149266A1 (en) | Exosomal compositions and methods for treating neurodegenerative diseases | |
US11129842B2 (en) | Methods and compositions for treating diseases related to imbalance of essential fatty acids | |
US20160228387A1 (en) | Solubilized formulation of coq10 for use in treatment of parkinson's disease | |
Zhang et al. | Preparation and evaluation of inhalable S-allylmercapto-N-acetylcysteine and nintedanib co-loaded liposomes for pulmonary fibrosis | |
WO2024025525A1 (en) | Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders | |
Attia et al. | The assessment of pharmacokinetics and neuroprotective effect of berberine hydrochloride-embedded albumin nanoparticles via various administration routes: comparative in-vivo studies in rats |